Original Article
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
N Engl J Med 2007; 356:1915-1927May 10, 2007
- Abstract
Background
Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate a quadrivalent vaccine against HPV types 6, 11, 16, and 18 (HPV-6/11/16/18) for the prevention of high-grade cervical lesions associated with HPV-16 and HPV-18.
Methods
In this randomized, double-blind trial, we assigned 12,167 women between the ages of 15 and 26 years to receive three doses of either HPV-6/11/16/18 vaccine or placebo, administered at day 1, month 2, and month 6. The primary analysis was performed for a per-protocol susceptible population that included 5305 women in the vaccine group and 5260 in the placebo group who had no virologic evidence of infection with HPV-16 or HPV-18 through 1 month after the third dose (month 7). The primary composite end point was cervical intraepithelial neoplasia grade 2 or 3, adenocarcinoma in situ, or cervical cancer related to HPV-16 or HPV-18.
Results
Subjects were followed for an average of 3 years after receiving the first dose of vaccine or placebo. Vaccine efficacy for the prevention of the primary composite end point was 98% (95.89% confidence interval [CI], 86 to 100) in the per-protocol susceptible population and 44% (95% CI, 26 to 58) in an intention-to-treat population of all women who had undergone randomization (those with or without previous infection). The estimated vaccine efficacy against all high-grade cervical lesions, regardless of causal HPV type, in this intention-to-treat population was 17% (95% CI, 1 to 31).
Conclusions
In young women who had not been previously infected with HPV-16 or HPV-18, those in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV-16 or HPV-18 than did those in the placebo group. (ClinicalTrials.gov number, NCT00092534.)
Media in This Article
Figure 1
Time until the Development of High-Grade Cervical Disease Associated with HPV-16, HPV-18, or Any HPV Type (Intention-to-Treat Population).Table 1
Baseline Characteristics of the Subjects.Article Activity
- Article
Cervical cancer is the second most common cancer in women and the leading cause of cancer-related death in many developing countries.1 Although well-organized programs for Papanicolaou screening have led to a significant decline in mortality from cervical cancer in developed countries,1 such programs are costly2 and have not been effectively implemented in most developing countries.3
Human papillomaviruses (HPVs) cause virtually all cervical cancers, with HPV types 16 (HPV-16) and 18 (HPV-18) responsible for approximately 70%.4 When phase 3 trials of prophylactic HPV vaccines were in the planning stages, the vaccine advisory committee of the Food and Drug Administration (FDA) recommended that these trials be powered to demonstrate efficacy in preventing high-grade cervical lesions that are classified as cervical intraepithelial neoplasia grade 2 or 3,5 a perspective endorsed by the World Health Organization (WHO).6 In this report, we describe the results of a phase 3 trial of a quadrivalent vaccine against HPV types 6, 11, 16, and 18 (HPV-6/11/16/18) designed to assess the prevention of cervical intraepithelial neoplasia grade 2 or 3, adenocarcinoma in situ, and cervical cancer caused by HPV-16 or HPV-18. HPV-6 and HPV-11, which are rarely detected in high-grade cervical lesions, cause the majority of anogenital warts.7,8 A report by Garland et al.9 on vaccine efficacy against external anogenital, vaginal, and cervical lesions associated with HPV types 6, 11, 16, and 18 appears elsewhere in this issue of the Journal.
Methods
Study Design
From June 2002 through May 2003, we enrolled 12,167 women between the ages of 15 and 26 years at 90 study sites in 13 countries in our ongoing double-blind, placebo-controlled, randomized trial. The institutional review board at each center approved the protocol; written informed consent was obtained from all subjects. Women were eligible to participate in the study if they were not pregnant, did not report abnormal results on a Papanicolaou smear, and had had a lifetime number of no more than four sex partners. Subjects were asked to use effective contraception during the vaccination period (day 1 through month 7).
The trial, which was called Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) II, was designed, managed, and analyzed by Merck in conjunction with external academic investigators and members of the external data and safety monitoring board. The academic authors had full access to the data and the analyses and approved the final manuscript. All authors vouch for the completeness and accuracy of the data presented.
Vaccine and Randomization
The quadrivalent HPV-6/11/16/18 virus-like–particle vaccine with amorphous aluminum hydroxyphosphate sulfate adjuvant (Gardasil, Merck) and a visually indistinguishable aluminum-containing placebo have been described previously.10 Subjects were randomly assigned to receive vaccine or placebo at day 1, month 2, and month 6 after having a negative result on a pregnancy test of the urine or blood. (Details regarding the randomization procedure can be found in the Supplementary Appendix, available with the full text of this article at www.nejm.org.) Subjects were observed for 30 minutes after receiving the injection and were asked to report serious adverse events occurring 1 to 15 days after each injection. A total of 916 subjects (all of the subjects at U.S. centers) were asked to use a vaccination report card to record all serious and nonserious adverse events occurring 1 to 15 days after each injection. Throughout the trial, all serious adverse events that were potentially related to either the procedure or the vaccine, all deaths, and all pregnancy outcomes were to be reported.
Clinical Follow-up
After randomization, the first-day visit included a gynecologic examination and the taking of a medical history with collection of cervical samples for Papanicolaou testing (ThinPrep, Cytyc) and anogenital swabs (of the labial, vulvar, perineal, perianal, endocervical, and ectocervical areas) for HPV DNA testing. Follow-up visits were scheduled 1 and 6 months after the third injection and at months 24, 36, and 48. (Details regarding specimen collection and HPV testing can be found in the Supplementary Appendix.)
Cervical Lesions
Referrals for colposcopy were standardized with the use of a mandatory Papanicolaou triage algorithm (Fig. 1 of the Supplementary Appendix). Colposcopists were trained to locate and biopsy all discrete abnormal areas on the cervix. Separate instruments were used to avoid HPV contamination. Biopsy samples were processed and adjacent histologic sections of each sample were first read for clinical management by pathologists at a central laboratory (Diagnostic Cytology Laboratories) who were unaware of treatment-group assignments and HPV status and then read for end-point determination by a panel of four pathologists who were unaware of diagnoses made at the central laboratory, clinical findings, treatment group, and HPV status. Subjects with cervical intraepithelial neoplasia with a severity of at least grade 2 or 3 were referred for definitive therapy.
Primary Hypothesis and End Points
The primary hypothesis stated that, as compared with placebo, the vaccine would reduce the incidence of high-grade cervical intraepithelial neoplasia related to HPV-16 or HPV-18 in the per-protocol susceptible population. End-point assignment was based on the blinded consensus diagnosis of at least two pathologists. The primary composite end point was cervical intraepithelial neoplasia grade 2 or 3, adenocarcinoma in situ, or invasive carcinoma of the cervix, with the detection of DNA from HPV-16, HPV-18, or both in one or more of three adjacent sections of the same lesion.9 The evaluations were performed with the use of WHO histologic criteria.11,12
Statistical Analysis
The study was powered on the basis of a fixed number of events with an interim analysis. To ensure adequate power for the interim analysis (a power of 80 to 90%, with a one-sided alpha of 0.0102) and the final analysis (a power of at least 90%, with a one-sided alpha of 0.02055) for true vaccine efficacy of 80 to 90%, at least 19 subjects with the primary composite end point were required for the interim analysis; at least 29 subjects with the primary composite end point were required for the final analysis. With an anticipated annual event rate of 0.19% for HPV-16–related end points and 0.038% for HPV-18–related end points, a total of 11,500 subjects were required for the study. The interim analysis for vaccine efficacy (approximately 1.5 years of follow-up after administration of the third dose, including all data from visits that occurred before June 11, 2005) showed 100% efficacy against high-grade cervical intraepithelial neoplasia related to HPV-16 or HPV-18 in the per-protocol population, with no subjects in the vaccine group and 21 in the placebo group (97.96% confidence interval [CI], 76 to 100). This analysis was part of the application for vaccine licensure, which was approved after priority review by the FDA on June 8, 2006. The analyses presented here include an additional year of follow-up with all data from visits that occurred on or before June 15, 2006.
The prespecified primary efficacy analysis (per-protocol analysis) was conducted among subjects who had negative results on DNA and serologic testing for HPV-16 or HPV-18 at enrollment, remained DNA-negative for the same HPV type through 1 month after the administration of the third dose of vaccine or placebo (month 7), received all doses within 1 year, and had no protocol violations. Follow-up for case ascertainment for this analysis started 1 month after the administration of the third dose of vaccine or placebo. The primary hypothesis was tested at the one-sided alpha level of 0.02055 with the use of a multiplicity adjustment13 to account for the interim analysis. A point estimate of vaccine efficacy and the 95.89% CI were calculated on the basis of the observed split between subjects receiving vaccine and those receiving placebo and the accrued person-time. The statistical criterion for success (P<0.02055) was equivalent to requiring that the lower bound of the 95.89% CI for vaccine efficacy would exclude 0%. An exact conditional procedure was used to evaluate vaccine efficacy under the assumption that the numbers of patients with high-grade cervical disease in the vaccine and placebo groups were independent Poisson random variables.14 For subjects who had more than one end-point event, only the first event in a category was counted as a case (defined as a consensus diagnosis), but a subject with more than one end-point event could be counted in more than one category of end-point events.
Analyses were conducted with respect to the primary end point, which was further characterized by lesion type and by positivity for HPV-16, HPV-18, or both. A woman with a lesion containing both HPV-16 and HPV-18 DNA or with different lesions showing various histologic grades was counted only once toward the primary composite end point and once for each of the component end points defined on the basis of HPV-16 or HPV-18 status or lesion grade.
To estimate vaccine efficacy in a population with less than perfect compliance, a prespecified supportive analysis was conducted in an unrestricted susceptible population that included all subjects who had negative results on polymerase-chain-reaction (PCR) and serologic assays to the relevant type of HPV at enrollment. We also estimated vaccine efficacy in an intention-to-treat population that included all subjects who had undergone randomization, regardless of baseline status with respect to HPV and cervical neoplasia. Follow-up for case ascertainment in these populations started 1 day after the first injection. The intention-to-treat population was used to evaluate the effect of vaccination on prevalent and incident HPV-16– or HPV-18–related high-grade disease and high-grade disease caused by either vaccine or nonvaccine HPV types. For the intention-to-treat-populations, cumulative incidence distributions15 for each vaccination group were computed and presented graphically with 95% CIs.
Subjects in the per-protocol susceptible population from whom serum samples were collected during predefined time frames were included in type-specific immunogenicity analyses. Adverse events were summarized for all vaccination visits as frequencies and percentages according to study group. Risk differences and associated 95% CIs (unadjusted for multiplicity) were computed comparing the vaccine group with the placebo group.
Results
A total of 12,707 women attended the enrollment visit. Of these, 12,167 (96%) met the eligibility requirements; of the eligible subjects, 6087 were randomly assigned to receive vaccine and 6080 to receive placebo. Baseline characteristics were similarly distributed between the two groups (Table 1Table 1
Baseline Characteristics of the Subjects.). At baseline, the results of Papanicolaou tests were abnormal for 11.8% of subjects in the vaccine group and 11.1% in the placebo group (Table 1). The most common reason for exclusion from the two prespecified populations for analysis of prophylactic efficacy was PCR-based detection of HPV-16 or HPV-18 DNA or antibodies at baseline (Table 1 and Table 2Table 2
Subjects Included in and Excluded from the Analyses.).In this ongoing study, subjects were followed for an average of 3 years after the administration of the first dose of vaccine or placebo. In the per-protocol susceptible population, which included 10,565 of 12,167 women who underwent randomization (87%), the vaccine prevented 98% of HPV-16/18–related high-grade cervical lesions (Table 3Table 3
Vaccine Efficacy against Cervical Intraepithelial Neoplasia Grade 2 or 3 or Adenocarcinoma In Situ Associated with HPV-16 or HPV-18 or Any HPV Type.). In this population, 1 woman in the vaccine group and 42 women in the placebo group received the diagnosis of cervical intraepithelial neoplasia grade 2 or 3 or cervical adenocarcinoma in situ associated with HPV-16, HPV-18, or both. The single subject whose disease was counted as a case (defined as a consensus diagnosis) of HPV-16–positive cervical intraepithelial neoplasia grade 3 in the vaccine group was positive for HPV-52 at baseline as well as in five histologic specimens collected at the time of diagnosis and treatment. HPV-16 DNA was detected in one histologic specimen but at no other time points.A total of 11,508 of 12,167 women who underwent randomization (95%) were included in the analysis of the unrestricted susceptible population. Vaccine efficacy remained high at 95% (Table 3). Cervical intraepithelial neoplasia grade 2 or 3 or adenocarcinoma in situ developed in 3 subjects in the vaccine group and in 62 in the placebo group. Of note, more than 99% of subjects in this population eventually received the full three-dose regimen.
To provide a preliminary assessment of the effect of quadrivalent vaccine on high-grade cervical disease related to HPV-16 or HPV-18 in a population that included women with and without prevalent cervical intraepithelial neoplasia and infection due to vaccine and nonvaccine HPV types at baseline, we performed an intention-to-treat analysis of all women who had undergone randomization (Figure 1AFigure 1
Time until the Development of High-Grade Cervical Disease Associated with HPV-16, HPV-18, or Any HPV Type (Intention-to-Treat Population). and Table 3). Vaccine efficacy was 44%, with high-grade cervical disease related to HPV-16 or HPV-18 developing in 83 subjects in the vaccine group and 148 in the placebo group. Most of the cases (defined as consensus diagnoses) that were added to the first intention-to-treat analysis (98%), as compared with those in the unrestricted susceptible population, were high-grade cervical disease caused by HPV-16 or HPV-18 infection that was present before the first injection. Vaccination did not appear to alter the course of cervical lesions related to HPV-16 or HPV-18 or of infection present at the time of randomization (Table 1 of the Supplementary Appendix). Thus, since the percentage of subjects with an end point associated with infection or disease that was prevalent at baseline decreased over time, the incidence of HPV-16–related or HPV-18–related cervical intraepithelial neoplasia grade 2 or 3 and adenocarcinoma in situ in the placebo group continued to increase while the incidence in the vaccine group began to plateau (Figure 1A). In the second intention-to-treat analysis, 219 subjects in the vaccine group and 266 in the placebo group had prevalent or incident high-grade cervical disease due to vaccine or nonvaccine HPV types, representing a reduction of 17% in the vaccine group (Figure 1B and Table 3). None of the women had invasive cervical cancer.Among women who tested negative for both HPV-16 and HPV-18 at enrollment (4693 in the vaccine group and 4703 in the placebo group), high-grade cervical disease developed in 95 subjects in the vaccine group and in 130 in the placebo group, a reduction of nearly 27% in the vaccine group (95% CI, 4 to 44). Women who were infected with only HPV-16 or HPV-18 appeared to be protected against disease caused by the type of HPV to which they had tested negative. Though the result was not significant, vaccine efficacy for women who tested positive for HPV-16 (773 in the vaccine group and 798 in the placebo group) appeared to be high for cervical intraepithelial neoplasia grade 2 or 3 and adenocarcinoma in situ caused by HPV-18 (no subjects in the vaccine group and 5 in the placebo group). Vaccine efficacy for women who tested positive for HPV-18 (257 subjects in the vaccine group and 253 in the placebo group) also appeared to be high for cervical intraepithelial neoplasia grade 2 or 3 and adenocarcinoma in situ caused by HPV-16 (no subjects in the vaccine group and 2 in the placebo group).
Among the 1512 vaccinated women in the immunogenicity substudy, more than 99% had seroconversion to the relevant vaccine-type HPV. At month 24, of those subjects in each type-specific per-protocol population included in the immunogenicity substudy, 96% of 986 subjects were seropositive for HPV-6, 97% of 987 were seropositive for HPV-11, 99% of 953 were seropositive for HPV-16, and 68% of 1059 were seropositive for HPV-18, as measured in specific neutralizing antibodies. Although the percentage of women in the vaccine group who maintained detectable levels of HPV-18 antibodies was lower than the percentage with HPV-16 antibodies, the efficacy for prevention of HPV-18–related high-grade lesions was maintained at 100% through follow-up in the unrestricted susceptible population (Table 3).
There were relatively few side effects of vaccination. The proportion of subjects who reported one or more injection-site adverse events was higher in the vaccine group than in the placebo group (84.4% vs. 77.9%), with the most common event being injection-site pain (risk difference, 6.5 percentage points; 95% CI, 1.4 to 11.7) (Table 4Table 4
Adverse Events.). One subject in the placebo group discontinued participation owing to a serious injection-related adverse event (hypersensitivity). The proportions of women reporting serious adverse events were similar in the two treatment groups. (All systemic and serious adverse events, categorized by organ system and treatment group, are provided in Tables 5 and 6 of the Supplementary Appendix.) Within these categories, there were nominally significant differences in the percentages of subjects in the vaccine group and the placebo group who reported seasonal allergies (10 in the vaccine group and 2 in the placebo group [risk difference, 1.8; 95% CI, 0.3 to 3.7]) and neck pain (2 in the vaccine group and 10 in the placebo group [risk difference, −1.8; 95% CI, −3.7 to −0.3]). No multiplicity adjustments were made for these comparisons. Adverse-event profiles were generally similar for women with and without antibodies to one or more of the vaccine-related HPV types at enrollment.Pregnancy was reported in 1053 subjects in the vaccine group and 1106 in the placebo group. For all phase 3 trials of the quadrivalent vaccine combined (Table 2 of the Supplementary Appendix), 1396 subjects in the vaccine group (13%) and 1436 in the placebo group (16%) had become pregnant, and outcomes were available for approximately 82%. The proportions of women with live births, difficulties with delivery, spontaneous abortions, and late fetal deaths were similar in the two study groups. Congenital anomalies were reported for 41 infants and 6 fetuses (25 in the vaccine group and 22 in the placebo group) (Table 3 of the Supplementary Appendix). A review by an external specialist who was unaware of study-group assignments concluded that the types of anomalies observed were diverse and consistent with those generally seen in young women.16
Further analyses were done to evaluate pregnancies with an estimated date of conception either within 30 days after any vaccination or more than 30 days after any vaccination (Table 4 of the Supplementary Appendix). For pregnancies with an estimated date of conception within 30 days after any vaccination, 19 of 112 in the vaccine group and 26 of 115 in the placebo group resulted in a spontaneous abortion (risk difference, −5.6; 95% CI, −16.1 to 4.8). Of the live-born infants, five were found to have a congenital anomaly (five in the vaccine group and none in the placebo group [risk difference, 4.5; 95% CI, 1.1 to 10.1]). The congenital anomalies observed in these five infants were relatively common and pathogenetically unrelated, suggesting different causes. For pregnancies with an estimated date of conception of more than 30 days after any vaccination, 266 of 1198 in the vaccine group and 283 of 1218 in the placebo group resulted in a spontaneous abortion (risk difference, −1.0; 95% CI, −4.4 to 2.3). A total of 20 infants or fetuses whose mothers were in the vaccine group and 22 whose mothers were in the placebo group were found to have a congenital anomaly (risk difference, −0.1; 95% CI, −1.2 to 1.0).
Discussion
When administered to subjects who had not been previously exposed to either HPV-16 or HPV-18, the prophylactic HPV vaccine was highly effective (98%) in preventing HPV-16–related and HPV-18–related cervical intraepithelial neoplasia grade 2 or 3 and adenocarcinoma in situ. Efficacy was lower (44%) for the population of all women who had undergone randomization, which also included subjects who had HPV-16–related or HPV-18–related cervical intraepithelial neoplasia or infection with HPV-16 or HPV-18 before the first injection. Although prevention of invasive cervical cancer is the main goal of prophylactic HPV vaccination, it is ethically unacceptable to use invasive cancer as the end point in efficacy trials. Cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ,12 which the International Federation of Obstetrics and Gynecology classifies as stage 0 noninvasive cervical cancers,17 are clinically important outcomes because they are likely to persist18-20 and may become invasive without treatment. Although a histologic diagnosis of cervical intraepithelial neoplasia grade 2 is less reproducible and spontaneous regression is more common than for grade 3,19,20 this lesion is also considered to be high grade.12
We took several steps to enhance accuracy, reproducibility, and generalizability of our findings. To ensure high sensitivity for histologic end points, colposcopists were instructed to biopsy all discrete abnormal areas; for high specificity, HPV-16 and HPV-18 DNA had to be detected in tissue sections. Histologic diagnoses were determined by a panel of expert gynecologic pathologists who were unaware of other clinical and laboratory data. Generalizability was enhanced by enrolling women from both developed and developing nations and by using standard Papanicolaou screening and management algorithms.21,22 Prophylactic vaccine efficacy was high for all four geographic regions and for all ethnic or racial groups and was similar to efficacy estimates from phase 2 trials of HPV-16 and HPV-18 infection,10,23 indicating the robustness of our findings.
The mean length of follow-up in this study was 3 years after administration of the first dose of vaccine or placebo. Within this interval, 42 subjects in the placebo group who were included in the per-protocol analysis became infected, and incident high-grade cervical disease related to HPV-16 or HPV-18 developed. As others have reported,24-28 the time from HPV infection to the development of a high-grade cervical lesion is often less than 24 months. These findings suggest that widespread immunization of female adolescents and young women could lead to reductions in HPV-16–related and HPV-18–related high-grade lesions that would be apparent within years, rather than decades.
Although follow-up was relatively short in duration, three previous phase 2 trials of prophylactic HPV recombinant vaccines included 4 to 5 years of follow-up28-30 and found no evidence of waning immunity or decreased efficacy for prevention of infection or persistent shedding of virus. Durability of vaccine-induced protection beyond 5 years is unknown. An antigen challenge of quadrivalent HPV-6/11/16/18 vaccine was shown to stimulate an anamnestic response, the hallmark of a vaccine that offers long-lasting protection.31 The planned 15-year follow-up of vaccinated subjects in northern Europe32 should provide essential information on the durability of protection.
Implementation of public health measures is challenging, owing to difficulties in maintaining compliance and to the heterogeneity of target populations. In this study, subjects were encouraged to comply with the three-dose vaccination regimen of administration at day 1, month 2, and month 6; however, subjects were not eliminated from the study if they deviated from this regimen. Analysis of the unrestricted susceptible population showed a high efficacy (95%), indicating that there is flexibility around the suggested regimen. Of note, it is likely that protective antibodies developed in some vaccinated women before they had received three doses, since infection with HPV-16 or HPV-18 before or within 1 month after receiving all three injections added 17 of 20 new cases in the placebo group and only 2 new cases in the vaccine group. On the other hand, there was no clear evidence that vaccination altered the course of HPV-16 or HPV-18 infection that was present before administration of the first vaccine dose.
It is likely that the population of women with prevalent HPV-16 or HPV-18 infection at trial entry was enriched for high-grade disease because high-grade lesions are more likely to persist than are low-grade lesions and because most HPV infections are transient.33 Speculation that elimination of HPV-16 and HPV-18 will open a niche for other high-risk viruses is not supported by the literature. Young women are often infected with multiple high-risk HPV types, and the risk of new infection is greater for women who are infected with one or more HPV types than for uninfected women.34-37 In addition, levels of viral DNA in clinical specimens may be higher for one HPV type when there is coinfection with another type.38
The quadrivalent vaccine is prophylactic, not therapeutic. Even in the setting of high vaccine coverage, routine screening for cervical cancer will be necessary to detect and treat disease caused by HPV-16 or HPV-18 infections acquired before vaccination and by other carcinogenic HPV types.
Prophylactic HPV vaccines must be safe and efficacious in diverse settings because women throughout the world are at risk for cervical cancer. In this trial and in a previous trial,10 no safety concerns among nonpregnant women were identified. Additional data on vaccination during pregnancy are needed. Since women with human immunodeficiency virus infection or other immunosuppressive conditions were not enrolled in our study, future trials will be needed to evaluate safety and efficacy in these populations.
These data demonstrate that a quadrivalent HPV-6/11/16/18 vaccine was highly effective in preventing high-grade cervical lesions associated with HPV-16 and HPV-18. Widespread immunization of female children and adolescents may result in a substantial decrease in HPV-16–related and HPV-18–related cervical disease, including cervical cancer.
Supported by Merck.
Drs. Barr, Boslego, Bryan, Esser, Lupinacci, Gause, Sings, and Taddeo and Ms. Hesley and Ms. Thornton report being either current or former employees of Merck and having an equity interest or holding stock options in the company. Drs. Bosch, Thoresen, Skjeldestad, Kjaer, Brown, Villa, Majewski, Kurman, Dillner, Sigurdsson, Olsson, Ault, Myers, García, Perez, Paavonen, Hernandez-Avila, and Muñoz report receiving consulting fees from or serving on paid advisory boards for Merck. Dr. Ault also reports receiving consulting fees from and serving on an advisory board for Gen-Probe and receiving grant support from GlaxoSmithKline. Dr. Bosch also reports receiving consulting fees from or serving on advisory boards for GlaxoSmithKline and Digene, receiving lecture fees from Merck and GlaxoSmithKline, and receiving research grants from Merck and GlaxoSmithKline through his institution for both vaccine clinical trials and epidemiologic studies. Drs. Ault, Brown, Villa, Dillner, Olsson, Kjaer, Tay, Ferris, Paavonen, Majewski, and Muñoz report receiving lecture fees from Merck, Sanofi Pasteur, and Merck Sharp & Dohme. Indiana University and Merck have a confidential agreement that pays the university on the basis of certain landmarks regarding the HPV vaccine. Dr. Brown receives a portion of these structured payments. Dr. Skjeldestad reports receiving funding from Merck for natural history studies of HPV infection. Dr. Myers reports receiving funding from Merck for conducting modeling studies of the effectiveness and cost-effectiveness of the vaccine in different settings. Drs. Perez, Kjaer, Lehtinen, Paavonen, Sigurdsson, Hernandez-Avila, Skjeldestad, Thoresen, García, Tay, Dillner, Olsson, Ault, Brown, Ferris, Koutsky, and Myers report receiving funding from Merck through their respective institutions to conduct clinical trials of this vaccine. No other potential conflict of interest relevant to this article was reported.
Source Information
Address reprint requests to Dr. Laura A. Koutsky at the Department of Epidemiology, University of Washington, Box 359933, Lake Union Place, Suite 300, 1914 N. 34th St., Seattle, WA 98103, or at kouts@u.washington.edu.
Members of the Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) II Study Group, who vouch for the completeness and accuracy of the data, are listed in the Appendix, along with other study participants.
Appendix
The following is a list of members of the FUTURE II study group and their affiliations: Luisa L. Villa, Ph.D., Ludwig Institute for Cancer Research, São Paulo; Gonzalo Perez, M.D., National Research Center, Group Saludcoop, Bogotá, Colombia; Susanne K. Kjaer, M.D., Institute of Cancer Epidemiology, Danish Cancer Society/Rigshospitalet, Copenhagen; Jorma Paavonen, M.D., University of Helsinki, Helsinki; Matti Lehtinen, M.D., National Public Health Institute, Oulu, Finland; Nubia Muñoz, M.D., International Agency for Research on Cancer, Lyon, France; Kristján Sigurdsson, M.D., National Cancer Detection Clinic, Icelandic Cancer Society, Reykjavik, Iceland; Mauricio Hernandez-Avila, M.D., National Institute of Public Health, Cuernavaca, Morelos, Mexico; Finn Egil Skjeldestad, M.D., the Foundation for Scientific and Industrial Research at the Norwegian Institute of Technology Health Research, Trondheim, Norway; Steinar Thoresen, M.D., Cancer Registry of Norway, Oslo; Patricia García, M.D., Universidad Peruana Cayetano Heredia, Lima, Peru; Slawomir Majewski, M.D., Center of Diagnostics and Treatment of Sexually Transmitted Diseases, Warsaw Medical University, Warsaw, Poland; Joakim Dillner, M.D., Lund University, Lund, Sweden; Sven-Eric Olsson, M.D., Karolinska Institute at Danderyd Hospital, Stockholm; Eng Hseon Tay, M.D., KK Women's and Children's Hospital, Singapore; F. Xavier Bosch, M.D., Institut d'Investigación Biomédica de Bellvitge, Barcelona; Kevin A. Ault, M.D., Emory University School of Medicine, Atlanta; Darron R. Brown, M.D., Indiana University School of Medicine, Indianapolis; Daron G. Ferris, M.D., Medical College of Georgia, Augusta; Laura A. Koutsky, Ph.D., University of Washington, Seattle (chair); Robert J. Kurman, M.D., Johns Hopkins University School of Medicine, Baltimore; Evan R. Myers, M.D., Duke University Medical Center, Durham, NC; and Eliav Barr, M.D., John Boslego, M.D., Janine Bryan, Ph.D., Mark T. Esser, Ph.D., Christine K. Gause, Ph.D., Teresa M. Hesley, M.P.H., Lisa C. Lupinacci, Ph.D., Heather L. Sings, Ph.D., Frank J. Taddeo, Ph.D., and Annemarie R Thornton, B.S., Merck Research Laboratories, West Point, PA. Other participants in the study were as follows: Data and Safety Monitoring Board: M. Boulos, J.T. Cox, F. Langmark, J. Modlin (chair), A. Muñoz, V. Odlind, E. Wilkinson. Pathology Panel: A. Ferenczy, R. Kurman (study group member), B. Ronett, M. Stoler. Primary Investigators: Brazil — G. Andreoni, L. Bahamondes, A. Camargos, R. Costa, R. De Andrade, E. Fedrizzi, R. Ferriani, M. Gonçalves, F. Laginha, J. Mendonça, E. Moreira Jr., B. Nonnenmacher, W. Taborda, D. Zanetta; Colombia — J. Ardila, N. Balcazar, I. Maldonado, F. Revollo, A. Ruiz; Denmark — E.S. Andersen, H. Djursing, T. Hansen, J.J. Jørgensen, L. Nilas, B. Ottesen, L.K. Petersen, S.G. Thomsen, K. Toftager-Larsen; Finland — D. Apter, M. Kekki, M. Kuortti, L. Lahti, Y. Lindroos, T. Lunnas, J. Paavonen (study group member), J. Palmroth; Iceland — K. Sigurdsson (study group member); Mexico — E. Lazcano, J. Zertuche; Norway — K. Dalaker, B. Eriksen, L.E. Ernø, B. Fiane, K. Hesla, M. Myhre Isachsen, O.E. Iversen, K. Kasin, M. Kristoffersen, T. Lunde, P.T. Nordmark, T. Nygaard, M. Onsrud, G. Riis-Johannessen, H. Schiøtz, F.E. Skjeldestad (study group member), H. Sundhagen, O. Sviggum, K.A. Trosterud; Peru — P. García (study group member), M. Penny, A. Vivar; Poland — A. Basta, K. Czajkowski, P. Knapp, M. Spaczynski; Puerto Rico — R. Barnes; Singapore — E.H. Tay (study group member); Sweden — K. Elfgren, E. Hardmeier, C. Hellsten, C. Hofte, P. Jensen, G. Johannisson, G.-B. Löwhagen, S.-E. Olsson (study group member), M. Steinwall, L. Tamsen, T. Varnauskas, A. Wikström; United Kingdom — G. Crawford; United States — B. Allen, K. Ault (study group member), D. Brown (study group member), R. Edwards, J. Comerci, A. Giuliano, S. Greer, K. Hatch, J. Kriesel, J. Lalezari, E. Partridge, R. Sperling, S. Spruance, J. Stapleton, P. Wright, P. Zedler. Statistical and Programming Support: K. McCarroll, L. Zhang, H. Zhou.
- References
References
1
Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase no. 5, version 2.0. Lyon, France: IARC Press, 2004. (Accessed April 13, 2007, at http://www-dep.iarc.fr/globocan/methods.htm.)
2
Insinga RP ,Glass AG ,Rush BB . The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 2004;191:114-120
CrossRef | Web of Science | Medline3
Goldie SJ ,Kuhn L ,Denny L ,Pollack A ,Wright TC . Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001;285:3107-3115[Erratum, JAMA 2001;286:1026.]
CrossRef | Web of Science | Medline4
Munoz N ,Bosch FX ,de Sanjose S , et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527
Full Text | Web of Science | Medline5
Preventive human papillomavirus (HPV) vaccines — regulatory briefing document on endpoints. V. Presented at the Vaccines and Related Biological Products Advisory Committee Meeting, Bethesda, MD, November 28–29, 2001. (Accessed April 13, 2007, at http://www.fda.gov/ohrms/dockets/ac/01/briefing/3805b1_01.htm.)
6
Pagliusi SR ,Aguado TA . Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23:569-578
CrossRef | Web of Science | Medline7
von Krogh G . Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001;11:598-604
Web of Science | Medline8
Wiley DJ ,Douglas J ,Beutner K , et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 2002;35:Suppl 2:S210-S224
CrossRef | Web of Science | Medline9
Garland SM ,Hernandez-Avila M ,Wheeler CM , et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-1943
Full Text | Web of Science | Medline10
Villa LL ,Costa RLR ,Petta CA , et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-278
CrossRef | Web of Science | Medline11
Tavassoli FA, Devilee P, eds. Pathology and genetics: tumours of the breast and female genital organs. Lyon, France: IARC Press, 2003.
12
Tumors of the cervix, vagina and vulva. Atlas of tumor pathology. 3rd series. Fascicle 4. Washington, DC: Armed Forces Institute of Pathology, 1992:44-55.
13
Wang SK ,Tsiatis AA . Approximately optimal one-parameter boundaries for group sequential trials. Biometrics 1987;43:193-199
CrossRef | Web of Science | Medline14
Chan ISF ,Bohidar NR . Exact power and sample size for vaccine efficacy studies. Commun Stat Theory Methods 1998;27:1305-1322
CrossRef | Web of Science15
Pocock SJ ,Clayton TC ,Altman DG . Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 2002;359:1686-1689
CrossRef | Web of Science | Medline16
European Surveillance of Congenital Anomalies home page. (Accessed April 13, 2007, at http://www.eurocat.ulster.ac.uk/.)
17
Benedet JL ,Bender H ,Jones H III ,Ngan HY ,Pecorelli S . FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet 2000;70:209-262
CrossRef | Web of Science | Medline18
Peto J ,Gilham C ,Deacon J , et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004;91:942-953
Web of Science | Medline19
ASCUS-LSIL Triage Study (ALTS) Group
Web of Science | Medline20
ASCUS-LSIL Triage Study (ALTS) Group
Web of Science | Medline21
Wright TC Jr ,Cox JT ,Massad LS ,Twiggs LB ,Wilkinson EJ . 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120-2129
CrossRef | Web of Science | Medline22
Ferris DG . The 2001 ASCCP management guidelines for cervical cytology. Am Fam Physician 2004;70:1866-1868
Web of Science | Medline23
Harper DM ,Franco EL ,Wheeler C , et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection of human papillomavirus type 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-1765
CrossRef | Web of Science | Medline24
Woodman CB ,Collins S ,Winter H , et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-1836
CrossRef | Web of Science | Medline25
Winer RL ,Kiviat NB ,Hughes JP , et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-738
CrossRef | Web of Science | Medline26
Koutsky LA ,Holmes KK ,Critchlow CW , et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-1278
Full Text | Web of Science | Medline27
Schiffman MH . New epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 1995;87:1345-1347
CrossRef | Web of Science | Medline28
Mao C ,Koutsky LA ,Ault KA , et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27[Erratum, Obstet Gynecol 2006;107:1425.]
CrossRef | Web of Science | Medline29
Villa LL ,Costa RLR ,Petta CA , et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-1466
CrossRef | Web of Science | Medline30
Harper DM ,Franco EL ,Wheeler CM , et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006;367:1247-1255
CrossRef | Web of Science | Medline31
Olsson SE, Villa LL, Costa RLR, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle vaccine. Vaccine (in press).
32
Lehtinen M ,Herrero R ,Mayaud P , et al. Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 2006;24:Suppl 3:S233-S241
CrossRef | Web of Science33
Moscicki AB ,Schiffman M ,Kjaer S ,Villa LL . Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 2006;24:Suppl 3:S42-S51
CrossRef | Web of Science34
Chua K-L ,Hjerpe A . Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer 1996;77:121-127
CrossRef | Web of Science | Medline35
Thomas KK ,Hughes JP ,Kuypers JM , et al. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000;182:1097-1102
CrossRef | Web of Science | Medline36
Liaw K-L ,Hildesheim A ,Burk RD , et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001;183:8-15
CrossRef | Web of Science | Medline37
Rousseau M-C ,Pereira JS ,Prado JC ,Villa LL ,Rohan TE ,Franco EL . Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 2001;184:1508-1517
CrossRef | Web of Science | Medline38
Weissenborn SJ ,Funke AM ,Hellmich M , et al. Oncogenic human papillomavirus DNA loads in human immunodeficiency virus-positive women with high-grade cervical lesions are strongly elevated. J Clin Microbiol 2003;41:2763-2767
CrossRef | Web of Science | Medline
- Citing Articles (413)
Citing Articles
1
Sun-Kuie Tay. (2012) Cervical cancer in the human papillomavirus vaccination era. Current Opinion in Obstetrics and Gynecology 24:1, 3-7
CrossRef2
, Susan Hariri, Elizabeth R. Unger, Suzanne E. Powell, Heidi M. Bauer, Nancy M. Bennett, Karen C. Bloch, Linda M. Niccolai, Sean Schafer, Lauri E. Markowitz. (2012) The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. Cancer Causes & Control 23:2, 281-288
CrossRef3
Daniel Echelman, Sarah Feldman. (2012) Management of Cervical Precancers: A Global Perspective. Hematology/Oncology Clinics of North America 26:1, 31-44
CrossRef4
Sarah M. Tiggelaar, Margaret J. Lin, Raphael P. Viscidi, Jia Ji, Jennifer S. Smith. (2012) Age-Specific Human Papillomavirus Antibody and Deoxyribonucleic Acid Prevalence: A Global Review. Journal of Adolescent Health 50:2, 110-131
CrossRef5
Christopher K. Fairley, Tim R.H. Read. (2012) Vaccination against sexually transmitted infections. Current Opinion in Infectious Diseases 25:1, 66-72
CrossRef6
C. Chao, N. P. Klein, C. M. Velicer, L. S. Sy, J. M. Slezak, H. Takhar, B. Ackerson, T. C. Cheetham, J. Hansen, K. Deosaransingh, M. Emery, K.-L. Liaw, S. J. Jacobsen. (2012) Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. Journal of Internal Medicine 271:2, 193-203
CrossRef7
Marjorie Jenkins, Maurizio Chiriva-Internati, Leonardo Mirandola, Catherine Tonroy, Sean S. Tedjarati, Nicole Davis, Nicholas D'Cunha, Lukman Tijani, Fred Hardwick, Diane Nguyen, W. Martin Kast, Everardo Cobos. (2012) Perspective for Prophylaxis and Treatment of Cervical Cancer: An Immunological Approach. International Reviews of Immunology 31:1, 3-21
CrossRef8
A.M. Kaufmann. (2012) Primäre Prävention des Zervixkarzinoms und dessen Vorstufen. Der Onkologe
CrossRef9
Karen K. L. Chan, Tracy T. C. Kwan, Tzy-Jyun Yao, Kar Fai Tam, Annie N. Y. Cheung, Hextan Y. S. Ngan. (2012) Human papillomavirus vaccine: What are women most concerned about?. Journal of Obstetrics and Gynaecology Research 38:1, 23-30
CrossRef10
Daron G. Ferris, Jennifer Waller, Ashley Dickinson, Courtney McCracken, Angela Goebel. (2012) Impact of Pap Test Compliance and Cervical Cancer Screening Intervals on Human Papillomavirus Vaccine Acceptance. Journal of Lower Genital Tract Disease 16:1, 39-44
CrossRef11
S. Khatun, S. M. Akram Hussain, S. Chowdhury, J. Ferdous, F. Hossain, S. R. Begum, M. Jahan, S. Tabassum, S. Khatun, A. F. Karim. (2012) Safety and Immunogenicity Profile of Human Papillomavirus-16/18 AS04 Adjuvant Cervical Cancer Vaccine: A Randomized Controlled Trial in Healthy Adolescent Girls of Bangladesh. Japanese Journal of Clinical Oncology 42:1, 36-41
CrossRef12
Dana Shanis, Melissa Merideth, Tajana Klepac Pulanic, Bipin N. Savani, Minoo Battiwalla, Pamela Stratton. (2012) Female Long-Term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation: Evaluation and Management. Seminars in Hematology 49:1, 83-93
CrossRef13
Veronika Učakar, Mario Poljak, Irena Klavs. (2012) Pre-vaccination prevalence and distribution of high-risk human papillomavirus (HPV) types in Slovenian women: A cervical cancer screening based study. Vaccine 30:2, 116-120
CrossRef14
Silvina Arrossi, Veronica Maceira, Melisa Paolino, Rengaswamy Sankaranarayan. (2012) Acceptability and uptake of HPV vaccine in Argentina before its inclusion in the immunization program: A population-based survey. Vaccine
CrossRef15
Dorien C Rijkaart, Johannes Berkhof, Lawrence Rozendaal, Folkert J van Kemenade, Nicole WJ Bulkmans, Daniëlle AM Heideman, Gemma G Kenter, Jack Cuzick, Peter JF Snijders, Chris JLM Meijer. (2012) Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. The Lancet Oncology 13:1, 78-88
CrossRef16
Wichai Termrungruanglert, Piyalamporn Havanond, Nipon Khemapech, Somrat Lertmaharit, Sathirakorn Pongpanich, Chonlakiet Khorprasert, Surasak Taneepanichskul. (2012) Cost and Effectiveness Evaluation of Prophylactic HPV Vaccine in Developing Countries. Value in Health 15:1, S29-S34
CrossRef17
Dorothy J. Wiley, Emmanuel V. Masongsong, Shuang Lu, Sings Heather L., Benissa Salem, Anna R. Giuliano, Kevin A. Ault, Richard M. Haupt, Darron R. Brown. (2012) Behavioral and sociodemographic risk factors for serological and DNA evidence of HPV6, 11, 16, 18 infections. Cancer Epidemiology
CrossRef18
N.H. Gaffga, E.W. Flagg, H.S. Weinstock, J.C. Shlay, K.G. Ghanem, L.A. Koutsky, P.R. Kerndt, K.K. Hsu, E.R. Unger, S.D. Datta. (2012) Monitoring HPV type-specific prevalence over time through clinic-based surveillance: A perspective on vaccine effectiveness. Vaccine
CrossRef19
Lucija Tomljenovic, Christopher A. Shaw. (2011) Human papillomavirus (HPV) vaccine policy and evidence-based medicine: Are they at odds?. Annals of Medicine1-12
CrossRef20
E. F. Dunne, A. Friedman, S. D. Datta, L. E. Markowitz, K. A. Workowski. (2011) Updates on Human Papillomavirus and Genital Warts and Counseling Messages From the 2010 Sexually Transmitted Diseases Treatment Guidelines. Clinical Infectious Diseases 53:suppl 3, S143-S152
CrossRef21
Rebecca Anhang Price, Jasmin A. Tiro, Mona Saraiya, Helen Meissner, Nancy Breen. (2011) Use of human papillomavirus vaccines among young adult women in the United States: An analysis of the 2008 National Health Interview Survey. Cancer 117:24, 5560-5568
CrossRef22
Anne Kehely. 2011. Assessing the Safety of Drugs Used in Oncology. , 625-643.
CrossRef23
Marc Arbyn, Lutz Gissmann, Achim Schneider, Andreas M Kaufmann. (2011) Highlights of the 27th International Papillomavirus Conference and Clinical Workshop: part 1. Future Virology 6:12, 1389-1396
CrossRef24
D. Lutringer-Magnin, J. Kalecinski, G. Barone, H. Borne, V. Regnier, P. Vanhems, F. Chauvin, C. Lasset. (2011) Perception et pratique de la vaccination HPV par les gynécologues : une étude quantitative et qualitative en Rhône-Alpes. Gynécologie Obstétrique & Fertilité 39:12, 687-693
CrossRef25
Ali Rowhani-Rahbar, Frances B. Alvarez, Janine T. Bryan, James P. Hughes, Stephen E. Hawes, Noel S. Weiss, Laura A. Koutsky. (2011) Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. Journal of Clinical Virology
CrossRef26
Richard M. Haupt, Cosette M. Wheeler, Darron R. Brown, Suzanne M. Garland, Daron G. Ferris, Jorma A. Paavonen, Matti O. Lehtinen, Marc Steben, Elmar A. Joura, Katherine E. D. Giacoletti, David R. Radley, Margaret K. James, Alfred J. Saah, Heather L. Sings, . (2011) Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. International Journal of Cancer 129:11, 2632-2642
CrossRef27
A. N. Burchell, F. Coutlee, P.-P. Tellier, J. Hanley, E. L. Franco. (2011) Genital Transmission of Human Papillomavirus in Recently Formed Heterosexual Couples. Journal of Infectious Diseases 204:11, 1723-1729
CrossRef28
M. Arbyn, X. Castellsague, S. de Sanjose, L. Bruni, M. Saraiya, F. Bray, J. Ferlay. (2011) Worldwide burden of cervical cancer in 2008. Annals of Oncology 22:12, 2675-2686
CrossRef29
Meng-Kan Chen, Hui-Fang Hung, Stephen Duffy, Amy Ming-Fang Yen, Hsiu-Hsi Chen. (2011) Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination. Journal of Evaluation in Clinical Practice 17:6, 1050-1058
CrossRef30
Kathryn P. Trayes, Kathryn M. Conniff. (2011) Q & A: Patient to Physician FAQs: Answers to Common Patient Questions About Vaccinations. Primary Care: Clinics in Office Practice 38:4, 763-776
CrossRef31
Jonathan C. Hilpert, Sarah K. Brem, Melissa L. Carrion, Jenefer Husman. (2011) Learning about HPV on the Internet: the moderating role of moral values. Sex Education1-14
CrossRef32
Jane Shen-Gunther, Jessica J. Shank, Vulihn Ta. (2011) Gardasil™ HPV vaccination: Surveillance of vaccine usage and adherence in a military population. Gynecologic Oncology 123:2, 272-277
CrossRef33
Richard M. Haupt, Heather L. Sings. (2011) The Efficacy and Safety of the Quadrivalent Human Papillomavirus 6/11/16/18 Vaccine Gardasil. Journal of Adolescent Health 49:5, 467-475
CrossRef34
A. Neumeyer-Gromen, N. Bodemer, S.M. Müller, G. Gigerenzer. (2011) Ermöglichen Medienberichte und Broschüren informierte Entscheidungen zur Gebärmutterhalskrebsprävention?. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 54:11, 1197-1210
CrossRef35
Luigi Buonaguro, Maria Tagliamonte, Maria Lina Tornesello, Franco M Buonaguro. (2011) Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Review of Vaccines 10:11, 1569-1583
CrossRef36
Vivien Tsu, Marjorie Murray. (2011) Limited benefit of HPV vaccination for sexually active women in developing countries. Vaccine 29:50, 9290-9291
CrossRef37
Palefsky, Joel M., Giuliano, Anna R., Goldstone, Stephen, Moreira, Edson D. Jr., Aranda, Carlos, Jessen, Heiko, Hillman, Richard, Ferris, Daron, Coutlee, Francois, Stoler, Mark H., Marshall, J. Brooke, Radley, David, Vuocolo, Scott, Haupt, Richard M., Guris, Dalya, Garner, Elizabeth I.O., . (2011) HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia. New England Journal of Medicine 365:17, 1576-1585
Full Text38
A. R. Kreimer, A. C. Rodriguez, A. Hildesheim, R. Herrero, C. Porras, M. Schiffman, P. Gonzalez, D. Solomon, S. Jimenez, J. T. Schiller, D. R. Lowy, W. Quint, M. E. Sherman, J. Schussler, S. Wacholder, . (2011) Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine. JNCI Journal of the National Cancer Institute 103:19, 1444-1451
CrossRef39
Franco Lori. (2011) DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS. Expert Review of Vaccines 10:10, 1371-1384
CrossRef40
Maribel Almonte, Peter Sasieni, Jack Cuzick. (2011) Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines. Best Practice & Research Clinical Obstetrics & Gynaecology 25:5, 617-629
CrossRef41
Gabriella M. Anic, Anna R. Giuliano. (2011) Genital HPV infection and related lesions in men. Preventive Medicine 53, S36-S41
CrossRef42
Ian H Frazer, Myron J Levin. (2011) Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer. Current Opinion in Virology 1:4, 268-279
CrossRef43
Sarah L. Goff, Kathleen M. Mazor, Shawn J. Gagne, Kristin C. Corey, Diane R. Blake. (2011) Vaccine counseling: A content analysis of patient–physician discussions regarding human papilloma virus vaccine. Vaccine 29:43, 7343-7349
CrossRef44
Linda M. Niccolai, Niti R. Mehta, James L. Hadler. (2011) Racial/Ethnic and Poverty Disparities in Human Papillomavirus Vaccination Completion. American Journal of Preventive Medicine 41:4, 428-433
CrossRef45
Paul L. McCormack, Elmar A. Joura. (2011) Spotlight on Quadrivalent Human Papillomavirus(Types 6, 11, 16, 18) Recombinant Vaccine(Gardasil®) in the Prevention of PremalignantGenital Lesions, Genital Cancer, and Genital Warts in Women†. BioDrugs 25:5, 339-343
CrossRef46
Carla J. Chibwesha, Susan Cu-Uvin. (2011) See-and-Treat Approaches to Cervical Cancer Prevention for HIV-Infected Women. Current HIV/AIDS Reports 8:3, 192-199
CrossRef47
Aimée R Kreimer, Paula González, Hormuzd A Katki, Carolina Porras, Mark Schiffman, Ana Cecilia Rodriguez, Diane Solomon, Silvia Jiménez, John T Schiller, Douglas R Lowy, Leen-Jan van Doorn, Linda Struijk, Wim Quint, Sabrina Chen, Sholom Wacholder, Allan Hildesheim, Rolando Herrero. (2011) Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. The Lancet Oncology 12:9, 862-870
CrossRef48
Sarah E. Church, Shawn M. Jensen, Christopher G. Twitty, Keith Bahjat, Hong-Ming Hu, Walter J. Urba, Bernard A. Fox. (2011) Multiple Vaccinations. The Cancer Journal 17:5, 379-396
CrossRef49
D. Riethmuller. (2011) Les vaccins HPV ou l’actuelle confusion des genres, et l’absolue nécessité de revenir aux fondamentaux. Journal de Gynécologie Obstétrique et Biologie de la Reproduction 40:5, 385-386
CrossRef50
M. Brisson, N. van de Velde, E. L. Franco, M. Drolet, M.-C. Boily. (2011) Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity. Journal of Infectious Diseases 204:3, 372-376
CrossRef51
Jin Hwi Kim, Seog Nyeon Bae, Chung Won Lee, Min Jong Song, Sung Jong Lee, Joo Hee Yoon, Keun Ho Lee, Soo Young Hur, Tae Chul Park, Jong Sup Park. (2011) A pilot study to investigate the treatment of cervical human papillomavirus infection with zinc-citrate compound (CIZAR®). Gynecologic Oncology 122:2, 303-306
CrossRef52
Sherri N. Sheinfeld Gorin, Beth A. Glenn, Rebecca B. Perkins. (2011) The human papillomavirus (HPV) vaccine and cervical cancer: Uptake and next steps. Advances in Therapy 28:8, 615-639
CrossRef53
Julia ML Brotherton, Dorota M Gertig. (2011) Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact. Expert Review of Anti-infective Therapy 9:8, 627-639
CrossRef54
T. A. Westra, M. H. Rozenbaum, R. M. Rogoza, H. W. Nijman, T. Daemen, M. J. Postma, J. C. Wilschut. (2011) Until Which Age Should Women Be Vaccinated Against HPV Infection? Recommendation Based on Cost-effectiveness Analyses. Journal of Infectious Diseases 204:3, 377-384
CrossRef55
Betty Chou, Lauren S. Krill, Bernice B. Horton, Christopher E. Barat, Cornelia L. Trimble. (2011) Disparities in Human Papillomavirus Vaccine Completion Among Vaccine Initiators. Obstetrics & Gynecology 118:1, 14-20
CrossRef56
Mary Penny, Rosario Bartolini, N. Rocio Mosqueira, D. Scott LaMontagne, Maria Ana Mendoza, Irma Ramos, Jennifer L. Winkler, Jose Villafana, Amynah Janmohamed, Aisha O. Jumaan. (2011) Strategies to vaccinate against cancer of the cervix: Feasibility of a school-based HPV vaccination program in Peru. Vaccine 29:31, 5022-5030
CrossRef57
Aaron AR Tobian, Ronald H Gray. (2011) Male foreskin and oncogenic human papillomavirus infection in men and their female partners. Future Microbiology 6:7, 739-745
CrossRef58
Lisa E. Manhart, Albert J. Burgess-Hull, Charles B. Fleming, Jennifer A. Bailey, Kevin P. Haggerty, Richard F. Catalano. (2011) HPV vaccination among a community sample of young adult women. Vaccine 29:32, 5238-5244
CrossRef59
X Castellsagué, N Muñoz, P Pitisuttithum, D Ferris, J Monsonego, K Ault, J Luna, E Myers, S Mallary, O M Bautista, J Bryan, S Vuocolo, R M Haupt, A Saah. (2011) End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. British Journal of Cancer 105:1, 28-37
CrossRef60
Paul K.S. Chan, Shih-Jen Liu, Jo L.K. Cheung, T.H. Cheung, Winnie Yeo, Pele Chong, Stephen Man. (2011) T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer. Journal of Medical Virology 83:6, 1023-1030
CrossRef61
S. De Flora, P. Bonanni. (2011) The prevention of infection-associated cancers. Carcinogenesis 32:6, 787-795
CrossRef62
G.M.C. Chadenier, E. Colzani, M. Faccini, C.R. Borriello, C. Bonazzi. (2011) Assessment of the first HPV vaccination campaign in two northern Italian health districts. Vaccine 29:26, 4405-4408
CrossRef63
Andreas Dietz, Gunnar Wichmann. (2011) Head and neck cancer: effective prevention in youth and predictive diagnostics for personalised treatment strategies according to biological differences. The EPMA Journal 2:2, 241-249
CrossRef64
Philip E. Castle, Alfio Rausa, Tameka Walls, Patti E. Gravitt, Edward E. Partridge, Vanessa Olivo, Shelley Niwa, Kerry Grace Morrissey, Laura Tucker, Hormuzd Katki, Isabel Scarinci. (2011) Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. Preventive Medicine 52:6, 452-455
CrossRef65
S. Capri, R. Gasparini, D. Panatto, N. Demarteau. (2011) Cost–consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles. Gynecologic Oncology 121:3, 514-521
CrossRef66
P. K. S. Chan, A. C. S. Luk, J.-S. Park, K. K. Smith-McCune, J. M. Palefsky, R. Konno, L. Giovannelli, F. Coutlee, S. Hibbitts, T.-Y. Chu, W. Settheetham-Ishida, M. A. Picconi, A. Ferrera, F. De Marco, Y.-L. Woo, T. Raiol, P. Pina-Sanchez, J. L. K. Cheung, J.-H. Bae, M. Z. Chirenje, T. Magure, A.-B. Moscicki, A. N. Fiander, R. Di Stefano, T.-H. Cheung, M. M. Y. Yu, S. K. W. Tsui, D. Pim, L. Banks. (2011) Identification of Human Papillomavirus Type 58 Lineages and the Distribution Worldwide. Journal of Infectious Diseases 203:11, 1565-1573
CrossRef67
Hee Jung Lee, Jin Ki Kim, Dong Hyun Kim, Moon Soo Yoon. (2011) Condyloma accuminatum treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, 18). Journal of the American Academy of Dermatology 64:6, e130-e132
CrossRef68
Kaijun TAY, Sun K TAY. (2011) The impact of cytology screening and HPV vaccination on the burden of cervical cancer. Asia-Pacific Journal of Clinical Oncology 7:2, 154-159
CrossRef69
Lauren R. Ditzian, Gizelka David-West, Mauricio Maza, Beatrix Hartmann, Taraneh Shirazian, Miriam Cremer. (2011) Cervical Cancer Screening in Low- and Middle-Income Countries. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78:3, 319-326
CrossRef70
Bree Weaver, Marcia Shew, Brahim Qadadri, Wanzhu Tu, Yan Tong, Cheryl Denski, J. Dennis Fortenberry, Darron Brown. (2011) Natural History of Multiple Human Papillomavirus Infections in Female Adolescents With Prolonged Follow-up. Journal of Adolescent Health 48:5, 473-480
CrossRef71
Ian H. Frazer, Graham R. Leggatt, Stephen R. Mattarollo. (2011) Prevention and Treatment of Papillomavirus-Related Cancers Through Immunization. Annual Review of Immunology 29:1, 111-138
CrossRef72
A. K. Chaturvedi, H. A. Katki, A. Hildesheim, A. C. Rodriguez, W. Quint, M. Schiffman, L.-J. Van Doorn, C. Porras, S. Wacholder, P. Gonzalez, M. E. Sherman, R. Herrero, . (2011) Human Papillomavirus Infection with Multiple Types: Pattern of Coinfection and Risk of Cervical Disease. Journal of Infectious Diseases 203:7, 910-920
CrossRef73
Jae Hong No, Mi-Kyung Kim, Yong-Tark Jeon, Yong-Beom Kim, Yong-Sang Song. (2011) Human papillomavirus vaccine: Widening the scope for cancer prevention. Molecular Carcinogenesis 50:4, 244-253
CrossRef74
Daniela Koleva, Paola Compadri, Anna Padula, Livio Garattini. (2011) Economic evaluation of human papilloma virus vaccination in the European Union: a critical review. Internal and Emergency Medicine 6:2, 163-174
CrossRef75
Kevin A. Ault, Elmar A. Joura, Susanne K. Kjaer, Ole-Erik Iversen, Cosette M. Wheeler, Gonzalo Perez, Darron R. Brown, Laura A. Koutsky, Suzanne M. Garland, Sven-Eric Olsson, Grace W.K. Tang, Daron G. Ferris, Jorma Paavonen, Marc Steben, F. Xavier Bosch, Slawomir Majewski, Nubia Muñoz, Heather L. Sings, Kathy Harkins, Mary Anne Rutkowski, Richard M. Haupt, Elizabeth I.O. Garner, . (2011) Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. International Journal of Cancer 128:6, 1344-1353
CrossRef76
Mark H. Stoler, Michelle D. Vichnin, Alex Ferenczy, Daron G. Ferris, Gonzalo Perez, Jorma Paavonen, Elmar A. Joura, Henning Djursing, Kristján Sigurdsson, Lucy Jefferson, Frances Alvarez, Heather L. Sings, Shuang Lu, Margaret K. James, Alfred Saah, Richard M. Haupt, . (2011) The accuracy of colposcopic biopsy: Analyses from the placebo arm of the Gardasil clinical trials. International Journal of Cancer 128:6, 1354-1362
CrossRef77
Luis Ignacio Verdú Martín. (2011) Eficacia de la vacuna frente al virus del papiloma humano en la prevención del cáncer de cérvix. Progresos de Obstetricia y Ginecología
CrossRef78
, José Ramet, Diego Esso, Zsofia Meszner. (2011) Position paper—HPV and the primary prevention of cancer; improving vaccine uptake by paediatricians. European Journal of Pediatrics 170:3, 309-321
CrossRef79
Justin M Julius, Lois Ramondeta, Katherine A Tipton, Lincy S Lal, Karen Schneider, Judith A Smith. (2011) Clinical Perspectives on the Role of the Human Papillomavirus Vaccine in the Prevention of Cancer. Pharmacotherapy 31:3, 280-297
CrossRef80
L. Gissmann, G. Gross. (2011) Prophylaktische HPV-Impfstoffe. Der Hautarzt 62:3, 201-205
CrossRef81
Giuliano, Anna R., Palefsky, Joel M., Goldstone, Stephen, Moreira, Edson D. Jr., Penny, Mary E., Aranda, Carlos, Vardas, Eftyhia, Moi, Harald, Jessen, Heiko, Hillman, Richard, Chang, Yen-Hwa, Ferris, Daron, Rouleau, Danielle, Bryan, Janine, Marshall, J. Brooke, Vuocolo, Scott, Barr, Eliav, Radley, David, Haupt, Richard M., Guris, Dalya, . (2011) Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males. New England Journal of Medicine 364:5, 401-411
Full Text82
Halla Thorsteinsdóttir, Monali Ray, Andrew Kapoor, Abdallah S. Daar. (2011) Health biotechnology innovation on a global stage. Nature Reviews Microbiology 9:2, 137-143
CrossRef83
Vincent C. Emery, Hermann Einsele, Sowsan Atabani, Tanzina Haque. (2011) Immunotherapy and Vaccination After Transplant: The Present, the Future. Hematology/Oncology Clinics of North America 25:1, 215-229
CrossRef84
T. C. Pomfret, J. M. Gagnon Jr, A. T. Gilchrist. (2011) Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. Journal of Clinical Pharmacy and Therapeutics 36:1, 1-9
CrossRef85
A. C. Rodriguez, M. Schiffman, R. Herrero, A. Hildesheim, S. Wacholder, R. D. Burk. (2011) Response. JNCI Journal of the National Cancer Institute 103:2, 158-159
CrossRef86
O. M. Bautista, A. Saah, N. Munoz. (2011) Re: Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia Grade 2/3: Critical Role of Duration of Infection. JNCI Journal of the National Cancer Institute 103:2, 158-158
CrossRef87
Christopher A. Klebanoff, Nicolas Acquavella, Zhiya Yu, Nicholas P. Restifo. (2011) Therapeutic cancer vaccines: are we there yet?. Immunological Reviews 239:1, 27-44
CrossRef88
Eszter Somogyi, Jianqing Xu, Ágnes Gudics, József Tóth, Attila L. Kovács, Franco Lori, Julianna Lisziewicz. (2011) A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV. Vaccine 29:4, 744-753
CrossRef89
S.L. Rosenthal, T.W. Weiss, G.D. Zimet, L. Ma, M.B. Good, M.D. Vichnin. (2011) Predictors of HPV vaccine uptake among women aged 19–26: Importance of a physician's recommendation. Vaccine 29:5, 890-895
CrossRef90
Edgar P. Simard, Elizabeth M. Ward, Rebecca Siegel, Ahmedin Jemal. (2011) Cancers with increasing incidence trends in the United States: 1999 through 2008. CA: A Cancer Journal for Cliniciansn/a-n/a
CrossRef91
A. Szarewski, W.A.J. Poppe, S.R. Skinner, C.M. Wheeler, J. Paavonen, P. Naud, J. Salmeron, S.-N. Chow, D. Apter, H. Kitchener, X. Castellsagué, J.C. Teixeira, J. Hedrick, U. Jaisamrarn, G. Limson, S. Garland, B. Romanowski, F.Y. Aoki, T.F. Schwarz, F.X. Bosch, D.M. Harper, K. Hardt, T. Zahaf, D. Descamps, F. Struyf, M. Lehtinen, G. Dubin, . (2011) Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. International Journal of Cancern/a-n/a
CrossRef92
Paul K.S. Chan, Tak-Hong Cheung, Wai-Hon Li, Mei Y. Yu, May Y.M. Chan, So-Fan Yim, Wendy C.S. Ho, Apple C.M. Yeung, King-Man Ho, H.K. Ng. (2011) Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China. International Journal of Cancern/a-n/a
CrossRef93
J. Dillner, M. Arbyn, E. Unger, L. Dillner. (2011) Monitoring of human papillomavirus vaccination. Clinical & Experimental Immunology 163:1, 17-25
CrossRef94
Charlene A. Wong, Mona Saraiya, Susan Hariri, Linda Eckert, Roberta I. Howlett, Lauri E. Markowitz, Julia M.L. Brotherton, Katy Sinka, Olga G. Martinez-Montañez, Susanne K. Kjaer, Eileen F. Dunne. (2011) Approaches to monitoring biological outcomes for HPV vaccination: Challenges of early adopter countries. Vaccine 29:5, 878-885
CrossRef95
Kazuhiro Takehara, Tamaki Toda, Toshinao Nishimura, Junichi Sakane, Yosuke Kawakami, Tomoya Mizunoe, Morie Nishiwaki, Kiyomi Taniyama. (2011) Human Papillomavirus Types 52 and 58 Are Prevalent in Uterine Cervical Squamous Lesions from Japanese Women. Pathology Research International 2011, 1-7
CrossRef96
Trond Michelsen, Ole-Erik Iversen. (2011) Masseundersøkelser mot gynekologisk kreft - status og fremtid. Tidsskrift for Den norske legeforening 131:16, 1550-1553
CrossRef97
Maryem Ansari, Ghazala Mehdi, S. H. Arif, Hena Ansari, Tamkin Khan. (2011) Smear patterns and spectrum of premalignant and malignant cervical epithelial lesions in postmenopausal Indian women: A hospital-based study. Diagnostic Cytopathologyn/a-n/a
CrossRef98
Brandon Horn, Judith Balk, Jeffrey I. Gold. (2011) Revisiting the Sham: Is It all Smoke and Mirrors?. Evidence-Based Complementary and Alternative Medicine 2011, 1-4
CrossRef99
AN Fiander. (2011) The prevention of cervical cancer in Africa. Women's Health 7:1, 121-132
CrossRef100
E. Vardas, A. R. Giuliano, S. Goldstone, J. M. Palefsky, E. D. Moreira, M. E. Penny, C. Aranda, H. Jessen, H. Moi, D. G. Ferris, K.-L. Liaw, J. B. Marshall, S. Vuocolo, E. Barr, R. M. Haupt, E. I. O. Garner, D. Guris. (2011) External Genital Human Papillomavirus Prevalence and Associated Factors Among Heterosexual Men on 5 Continents. Journal of Infectious Diseases 203:1, 58-65
CrossRef101
Ho Sun Park. (2011) Systemic Review for Efficacy of Human Papillomavirus Vaccines. Journal of Bacteriology and Virology 41:4, 313
CrossRef102
Vernon J Lee, Sun Tay, Yee Teoh, Mei Tok. (2011) Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health 11:1, 203
CrossRef103
Jennifer S. Smith, Adam K. Lewkowitz, You-Lin Qiao, Jia Ji, Shangying Hu, Wen Chen, Rong Zhang, Kai Li Liaw, Mark Esser, Frank J. Taddeo, Robert G. Pretorius, Jerome L. Belinson. (2011) Population-based human papillomavirus 16,18, 6 and 11 DNA positivity and seropositivity in chinese women. International Journal of Cancern/a-n/a
CrossRef104
Paul L. McCormack, Elmar A. Joura. (2010) Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®). Drugs 70:18, 2449-2474
CrossRef105
M. Safaeian, C. Porras, M. Schiffman, A. C. Rodriguez, S. Wacholder, P. Gonzalez, W. Quint, L.-J. van Doorn, M. E. Sherman, V. Xhenseval, R. Herrero, A. Hildesheim, . (2010) Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections. JNCI Journal of the National Cancer Institute 102:21, 1653-1662
CrossRef106
J. Monsonego, J. Cortes, C. Greppe, M. Hampl, E. Joura, A. Singer. (2010) Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine. Vaccine 28:51, 8065-8072
CrossRef107
Marie-Hélène Mayrand, Eduardo L Franco. (2010) Integrating novel primary- and secondary-prevention strategies: the next challenge for cervical cancer control. Future Oncology 6:11, 1725-1733
CrossRef108
Elaine H. Lim, Shi Len Ng, Jia Liang Li, Alexander R. Chang, Joseph Ng, A. Ilancheran, Jeffrey Low, Swee Chong Quek, Eng Hseon Tay. (2010) Cervical dysplasia: Assessing methylation status (Methylight) of CCNA1, DAPK1, HS3ST2, PAX1 and TFPI2 to improve diagnostic accuracy. Gynecologic Oncology 119:2, 225-231
CrossRef109
J. C. Gage, P. E. Castle. (2010) Preventing Cervical Cancer Globally by Acting Locally: If Not Now, When?. JNCI Journal of the National Cancer Institute 102:20, 1524-1527
CrossRef110
Yuk-Ching Yip, Karry L.K. Ngai, Heong-Ting Vong, Lawrence C.H. Tzang, Shenglin Ji, Mengsu Yang, Paul K.S. Chan. (2010) Prevalence and genotype distribution of cervical human papillomavirus infection in Macao. Journal of Medical Virology 82:10, 1724-1729
CrossRef111
Maria A de Peuter, Kavi J Littlewood, Lieven Annemans, Nathalie Largeron, Sibilia Quilici. (2010) Cost–effectiveness of catch-up programs in human papillomavirus vaccination. Expert Review of Vaccines 9:10, 1187-1201
CrossRef112
R. Sankaranarayanan, P. Boffetta. (2010) Research on cancer prevention, detection and management in low- and medium-income countries. Annals of Oncology 21:10, 1935-1943
CrossRef113
Myron J Levin, Anna-Barbara Moscicki, Lin-Ye Song, Terrence Fenton, William A Meyer, Jennifer S Read, Edward L Handelsman, Barbara Nowak, Carlos A Sattler, Alfred Saah, David R Radley, Mark T Esser, Adriana Weinberg. (2010) Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years Old. JAIDS Journal of Acquired Immune Deficiency Syndromes 55:2, 197-204
CrossRef114
L. David Wise, Cindy J. Pauley, Bindhu Michael, Jayanthi J. Wolf. (2010) Lack of effects on male fertility from a quadrivalent HPV vaccine in Sprague-Dawley rats. Birth Defects Research Part B: Developmental and Reproductive Toxicology 89:5, 376-381
CrossRef115
D C Rijkaart, V M H Coupe, F J van Kemenade, D A M Heideman, A T Hesselink, W Verweij, L Rozendaal, R H Verheijen, P J Snijders, J Berkhof, C J L M Meijer. (2010) Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. British Journal of Cancer 103:7, 939-946
CrossRef116
M. Evans, N.G. Powell. (2010) The Changing Aetiology of Head and Neck Cancer: the Role of Human Papillomavirus. Clinical Oncology 22:7, 538-546
CrossRef117
Roman Rouzier, Jean-Pierre Giordanella. (2010) Coverage and Compliance of Human Papillomavirus Vaccines in Paris: Demonstration of Low Compliance With Non-School-Based Approaches. Journal of Adolescent Health 47:3, 237-241
CrossRef118
Thazin Hlaing, Yuk-Ching Yip, Karry L.K. Ngai, Heong-Ting Vong, Sio-In Wong, Wendy C.S. Ho, Sellma L.S.C. Batalha, Paul K.S. Chan. (2010) Distribution of human papillomavirus genotypes among cervical intraepithelial neoplasia and invasive cancers in Macao. Journal of Medical Virology 82:9, 1600-1605
CrossRef119
Loretta Brabin, Henry C Kitchener, Peter L Stern. (2010) Implementation of prophylactic HPV vaccination: progress and future challenges. Expert Review of Obstetrics & Gynecology 5:5, 591-603
CrossRef120
M. Obradovic, A. Mrhar, M. Kos. (2010) Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia. The European Journal of Public Health 20:4, 415-421
CrossRef121
K. Sigurdsson. (2010) Cervical cancer: cytological cervical screening in Iceland and implications of HPV vaccines. Cytopathology 21:4, 213-222
CrossRef122
Richard M Haupt, Carlos Sattler. (2010) HPV vaccine continues to be safe and effective, and its benefits continue to outweigh its risks. Expert Review of Vaccines 9:7, 697-701
CrossRef123
Daron G. Ferris, Lee Cromwell, Jennifer L. Waller, Leslie Horn. (2010) Most Parents Do Not Think Receiving Human Papillomavirus Vaccine Would Encourage Sexual Activity in Their Children. Journal of Lower Genital Tract Disease 14:3, 179-184
CrossRef124
Paolo Bonanni, Catherine Cohet, Susanne K. Kjaer, Nina B. Latham, Paul-Henri Lambert, Keith Reisinger, Richard M. Haupt. (2010) A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD®. Vaccine 28:30, 4719-4730
CrossRef125
Lauri E. Markowitz, Susan Hariri, Elizabeth R. Unger, Mona Saraiya, S. Deblina Datta, Eileen F. Dunne. (2010) Post-licensure monitoring of HPV vaccine in the United States. Vaccine 28:30, 4731-4737
CrossRef126
Vincent C. Emery, Hermann Einsele, Sowsan Atabani, Tanzina Haque. (2010) Immunotherapy and Vaccination After Transplant: The Present, the Future. Infectious Disease Clinics of North America 24:2, 515-529
CrossRef127
Suzanne M. Garland, Jennifer S. Smith. (2010) Human Papillomavirus Vaccines. Drugs 70:9, 1079-1098
CrossRef128
Päivi Laukkanen, Esa Läärä, Pentti Koskela, Eero Pukkala, Hanna Virkkunen, Matti Lehtinen. (2010) Population fraction of cervical neoplasia attributable to high-risk human papillomaviruses. Future Oncology 6:5, 709-716
CrossRef129
Mark A. Kane. (2010) Global implementation of human papillomavirus (HPV) vaccine: Lessons from hepatitis B vaccine. Gynecologic Oncology 117:2, S32-S35
CrossRef130
Yoon Hong Choi, Mark Jit, Nigel Gay, Andrew Cox, Geoff P. Garnett, William John Edmunds. (2010) Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 28:24, 4091-4102
CrossRef131
Archana Chatterjee, Catherine O’Keefe. (2010) Current controversies in the USA regarding vaccine safety. Expert Review of Vaccines 9:5, 497-502
CrossRef132
Jack Cuzick. (2010) Long-term cervical cancer prevention strategies across the globe. Gynecologic Oncology 117:2, S11-S14
CrossRef133
Douglas M. Molina, Sukumar Pal, Mathew A. Kayala, Andy Teng, Paul J. Kim, Pierre Baldi, Philip L. Felgner, Xiaowu Liang, Luis M. de la Maza. (2010) Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarrays. Vaccine 28:17, 3014-3024
CrossRef134
Joel M. Palefsky. (2010) Human Papillomavirus-Related Disease in Men: Not Just a Women's Issue. Journal of Adolescent Health 46:4, S12-S19
CrossRef135
María de Oña, Marta E. Alvarez-Argüelles, Magdalena Torrents, Laura Villa, Asunción Rodriguez-Feijoo, Ana Palacio, Jose A. Boga, Angel Tamargo, Santiago Melón. (2010) Prevalence, evolution, and features of infection with human papillomavirus: A 15-year longitudinal study of routine screening of a women population in the north of Spain. Journal of Medical Virology 82:4, 597-604
CrossRef136
Anil K. Chaturvedi. (2010) Beyond Cervical Cancer: Burden of Other HPV-Related Cancers Among Men and Women. Journal of Adolescent Health 46:4, S20-S26
CrossRef137
A. Dee, F. Howell. (2010) A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. The European Journal of Public Health 20:2, 213-219
CrossRef138
C. M. Wetmore, L. E. Manhart, J. N. Wasserheit. (2010) Randomized Controlled Trials of Interventions to Prevent Sexually Transmitted Infections: Learning From the Past to Plan for the Future. Epidemiologic Reviews 32:1, 121-136
CrossRef139
Max Kling, Joshua A. Zeichner. (2010) The role of the human papillomavirus (HPV) vaccine in developing countries. International Journal of Dermatology 49:4, 377-379
CrossRef140
Frank H. Lee, Valerie A. Paz-Soldan, Cesar Carcamo, Patricia J. Garcia. (2010) Knowledge and Attitudes of Adult Peruvian Women vis-à-vis Human Papillomavirus (HPV), Cervical Cancer, and the HPV Vaccine. Journal of Lower Genital Tract Disease 14:2, 113-117
CrossRef141
N. Munoz, S. K. Kjaer, K. Sigurdsson, O.-E. Iversen, M. Hernandez-Avila, C. M. Wheeler, G. Perez, D. R. Brown, L. A. Koutsky, E. H. Tay, P. J. Garcia, K. A. Ault, S. M. Garland, S. Leodolter, S.-E. Olsson, G. W. K. Tang, D. G. Ferris, J. Paavonen, M. Steben, F. X. Bosch, J. Dillner, W. K. Huh, E. A. Joura, R. J. Kurman, S. Majewski, E. R. Myers, L. L. Villa, F. J. Taddeo, C. Roberts, A. Tadesse, J. T. Bryan, L. C. Lupinacci, K. E. D. Giacoletti, H. L. Sings, M. K. James, T. M. Hesley, E. Barr, R. M. Haupt. (2010) Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women. JNCI Journal of the National Cancer Institute 102:5, 325-339
CrossRef142
J Cuzick, A Castañón, P Sasieni. (2010) Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20–29 in the UK. British Journal of Cancer 102:5, 933-939
CrossRef143
Charlene Wong, Jamie Krashin, Alison Rue-Cover, Mona Saraiya, Elizabeth Unger, Angela Calugar, Lauri Markowitz. (2010) Invasive and In Situ Cervical Cancer Reported to the Vaccine Adverse Event Reporting System (VAERS). Journal of Women's Health 19:3, 365-370
CrossRef144
Kristen Intemann, Inmaculada Melo-Martín. (2010) Social values and scientific evidence: the case of the HPV vaccines. Biology & Philosophy 25:2, 203-213
CrossRef145
María E. Fernández, Jennifer D. Allen, Ritesh Mistry, Jessica A. Kahn. (2010) Integrating Clinical, Community, and Policy Perspectives on Human Papillomavirus Vaccination. Annual Review of Public Health 31:1, 235-252
CrossRef146
A.M. Kaufmann, S. Nitschmann. (2010) Impfung gegen humane Papillomaviren. Der Internist 51:3, 410-414
CrossRef147
Sara Mirzendehdel, Seyed Alireza Nadji, Payam Tabarsi, Parvaneh Baghaei, Pedram Javanmard, Afsaneh Sigarroodi, Mohsen Fekrat. (2010) Prevalence of HPV and HIV among female drug addicts attending a drop-in center in Tehran, Iran. International Journal of Gynecology & Obstetrics 108:3, 254-255
CrossRef148
David J. Adelstein, Cristina P. Rodriguez. (2010) Human Papillomavirus: Changing Paradigms in Oropharyngeal Cancer. Current Oncology Reports 12:2, 115-120
CrossRef149
Shiwen Peng, Simon R. Best, Chien-Fu Hung, Myriam Loyo, Sofia Lyford-Pike, Paul W. Flint, David E. Tunkel, John R. Saunders, T. C. Wu, Sara I. Pai. (2010) Characterization of human papillomavirus type 11-specific immune responses in a preclinical model. The Laryngoscope 120:3, 504-510
CrossRef150
Neerja Bhatla, Vanita Suri, Partha Basu, Surendra Shastri, Sanjoy K. Datta, Dan Bi, Dominique J. Descamps, Hans L. Bock, . (2010) Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. Journal of Obstetrics and Gynaecology Research 36:1, 123-132
CrossRef151
Ha Linh Vu, Andrew G. Sikora, Shibo Fu, Johnny Kao. (2010) HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Letters 288:2, 149-155
CrossRef152
Maria Sophia Mackroth, Kathleen Irwin, Jos Vandelaer, Joachim Hombach, Linda O. Eckert. (2010) Immunizing school-age children and adolescents: Experience from low- and middle-income countries. Vaccine 28:5, 1138-1147
CrossRef153
Damjan S Nikolic, Vincent Piguet. (2010) Vaccines and Microbicides Preventing HIV-1, HSV-2, and HPV Mucosal Transmission. Journal of Investigative Dermatology 130:2, 352-361
CrossRef154
Peter C. Austin, Andrea Manca, Merrick Zwarenstein, David N. Juurlink, Matthew B. Stanbrook. (2010) A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: a review of trials published in leading medical journals. Journal of Clinical Epidemiology 63:2, 142-153
CrossRef155
Stan L. Block, Darron R. Brown, Archana Chatterjee, Michael A. Gold, Heather L. Sings, Anne Meibohm, Adrian Dana, Richard M. Haupt, Eliav Barr, Gretchen M. Tamms, Haiping Zhou, Keith S. Reisinger. (2010) Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine. The Pediatric Infectious Disease Journal 29:2, 95-101
CrossRef156
Robert B. Mandell, Ramesh Koukuntla, Laura J.K. Mogler, Andrea K. Carzoli, Alexander N. Freiberg, Michael R. Holbrook, Brian K. Martin, William R. Staplin, Nicholas N. Vahanian, Charles J. Link, Ramon Flick. (2010) A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge. Virology 397:1, 187-198
CrossRef157
Isabel C. Scarinci, Francisco A.R. Garcia, Erin Kobetz, Edward E. Partridge, Heather M. Brandt, Maria C. Bell, Mark Dignan, Grace X. Ma, Jane L. Daye, Philip E. Castle. (2010) Cervical cancer prevention. CancerNA-NA
CrossRef158
Alison C. Budd, Christine J. Sturrock. (2010) Cytology and cervical cancer surveillance in an era of human papillomavirus vaccination. Sexual Health 7:3, 328
CrossRef159
Helen Kent, Margaret E. Heffernan, Julie Silvers, Elya Moore, Suzanne M. Garland. (2010) Role of the nurse immuniser in implementing and maintaining the National Human Papillomavirus 'Cervical Cancer' Vaccine rollout through a school-based program in Victoria. Sexual Health 7:3, 391
CrossRef160
Leslie Horn, Casey Howard, Jennifer Waller, Daron G. Ferris. (2010) Opinions of Parents About School-Entry Mandates for the Human Papillomavirus Vaccine. Journal of Lower Genital Tract Disease 14:1, 43-48
CrossRef161
Peter L. Stern. (2010) For debate: that Australia should consider changing to the bivalent vaccine. Sexual Health 7:3, 238
CrossRef162
Ian H. Frazer. (2010) Cervical cancer vaccine development. Sexual Health 7:3, 230
CrossRef163
Jacob Bornstein. (2010) The HPV vaccine market: Cervarix™ competes with Gardasil ®. Therapy 7:1, 71-75
CrossRef164
Hossein Sadeghi-Nejad, Marlene Wasserman, Wolfgang Weidner, Daniel Richardson, David Goldmeier. (2010) Sexually Transmitted Diseases and Sexual Function. Journal of Sexual Medicine 7:1pt2, 389-413
CrossRef165
Anna-Barbara Moscicki, J. Thomas Cox. (2010) Practice Improvement in Cervical Screening and Management (PICSM). Journal of Lower Genital Tract Disease 14:1, 73-81
CrossRef166
Karen Canfell. (2010) Models of cervical screening in the era of human papillomavirus vaccination. Sexual Health 7:3, 359
CrossRef167
Ilkka Kalliala, Tadeusz Dyba, Pekka Nieminen, Timo Hakulinen, Ahti Anttila. (2010) Mortality in a long-term follow-up after treatment of CIN. International Journal of Cancer 126:1, 224-231
CrossRef168
EJ Crosbie, L Brabin. (2010) Cervical cancer: problem solved? Vaccinating girls against human papillomavirus. BJOG: An International Journal of Obstetrics & Gynaecology 117:2, 137-142
CrossRef169
Chan Joo Kim, Tae Chul Park, Jong Sup Park. (2010) Efficacy of human papillomavirus vaccines including cross protection : A review of recent evidence. Korean Journal of Obstetrics and Gynecology 53:2, 103
CrossRef170
Margaret E. Heffernan, Suzanne M. Garland, Mark A. Kane. (2010) Global reduction of cervical cancer with human papillomavirus vaccines: insights from the hepatitis B virus vaccine experience. Sexual Health 7:3, 383
CrossRef171
Suzanne M. Garland, Julia M. L. Brotherton, Christopher K. Fairley, Dorota M. Gertig, Marion Saville. (2010) Advancements in the control of genital human papillomavirus infections and related diseases: highlighting Australia's role. Sexual Health 7:3, 227
CrossRef172
A. E. Albers, L. Strauss, T. Liao, T. K. Hoffmann, A. M. Kaufmann. (2010) T Cell-Tumor Interaction Directs the Development of Immunotherapies in Head and Neck Cancer. Clinical and Developmental Immunology 2010, 1-14
CrossRef173
Sally L. Hodder, Debra Chew, Shobha Swaminathan. 2010. Adult Immunization in Women and Men. , 563-582.
CrossRef174
Stephen Inglis. 2009. HPV Vaccine. .
CrossRef175
Emma L. Ivansson, Inger M. Gustavsson, Erik Wilander, Patrik K.E. Magnusson, Ulf B. Gyllensten. (2009) Temporal trends over 3 decades and intrafamilial clustering of HPV types in Swedish patients with cervical cancer in situ. International Journal of Cancer 125:12, 2930-2935
CrossRef176
Katherine Flores, Christopher Bencomo. (2009) Preventing Cervical Cancer in the Latina Population. Journal of Women's Health 18:12, 1935-1943
CrossRef177
Timo Vesikari, Pierre Van Damme, Niklas Lindblad, Ulrich Pfletschinger, David Radley, Desmond Ryan, Scott Vuocolo, Richard M. Haupt, Dalya Guris. (2009) An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine Given Concomitantly With Diphtheria, Tetanus, Pertussis, and Poliomyelitis Vaccine in Healthy Adolescents 11 to 17 Years of Age. The Pediatric Infectious Disease Journal1
CrossRef178
G. Breitenecker. (2009) Zervixkarzinom-Screening. Der Pathologe 30:S2, 128-135
CrossRef179
Gary M Clifford. (2009) Global access to HPV vaccination: what are we waiting for?. The Lancet 374:9706, 1948-1949
CrossRef180
&NA;. (2009) Update on Quadrivalent Human Papillomavirus Vaccination and Pregnancy Outcomes. Obstetrics & Gynecology 114:6, 1168-1169
CrossRef181
Suzanne M. Garland, Kevin A. Ault, Stanley A. Gall, Jorma Paavonen, Heather L. Sings, Karen L. Ciprero, Alfred Saah, Deborah Marino, Desmond Ryan, David Radley, Haiping Zhou, Richard M. Haupt, Elizabeth I. O. Garner. (2009) Pregnancy and Infant Outcomes in the Clinical Trials of a Human Papillomavirus Type 6/11/16/18 Vaccine. Obstetrics & Gynecology 114:6, 1179-1188
CrossRef182
E. J. Kwak, K. Julian, . (2009) Human Papillomavirus Infection in Solid Organ Transplant Recipients. American Journal of Transplantation 9, S151-S160
CrossRef183
Zainab A. Malik, Susan M. Hailpern, Robert D. Burk. (2009) Persistent Antibodies to HPV Virus-Like Particles Following Natural Infection Are Protective Against Subsequent Cervicovaginal Infection with Related and Unrelated HPV. Viral Immunology 22:6, 445-449
CrossRef184
Diane M Harper. (2009) Currently approved prophylactic HPV vaccines. Expert Review of Vaccines 8:12, 1663-1679
CrossRef185
Theodoros Agorastos, Konstantinos Chatzigeorgiou, Julia M.L. Brotherton, Suzanne M. Garland. (2009) Safety of human papillomavirus (HPV) vaccines: A review of the international experience so far. Vaccine 27:52, 7270-7281
CrossRef186
Krista J. Hachey, Rebecca H. Allen, Melissa Nothnagle, Lori A. Boardman. (2009) Requiring Human Papillomavirus Vaccine for Immigrant Women. Obstetrics & Gynecology 114:5, 1135-1139
CrossRef187
Ian J. Amanna, Mark K. Slifka. (2009) Wanted, dead or alive: New viral vaccines. Antiviral Research 84:2, 119-130
CrossRef188
Hormuzd A Katki, Sholom Wacholder, Diane Solomon, Philip E Castle, Mark Schiffman. (2009) Risk estimation for the next generation of prevention programmes for cervical cancer. The Lancet Oncology 10:11, 1022-1023
CrossRef189
Magdalena Grce. (2009) Primary and secondary prevention of cervical cancer. Expert Review of Molecular Diagnostics 9:8, 851-857
CrossRef190
Mark Schiffman, Mahboobeh Safaeian, Nicolas Wentzensen. (2009) The Use of Human Papillomavirus Seroepidemiology to Inform Vaccine Policy. Sexually Transmitted Diseases 36:11, 675-679
CrossRef191
Diane M Harper. (2009) Current prophylactic HPV vaccines and gynecologic premalignancies. Current Opinion in Obstetrics and Gynecology1
CrossRef192
Y. Deleré. (2009) Die Impfung gegen HPV. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 52:11, 1065-1068
CrossRef193
Franco Maria Buonaguro, Maria Lina Tornesello, Luigi Buonaguro. (2009) Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Review of Vaccines 8:10, 1379-1398
CrossRef194
Elsebeth Lynge, Ahti Antilla, Marc Arbyn, Nereo Segnan, Guglielmo Ronco. (2009) What’s next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination. European Journal of Cancer 45:15, 2714-2721
CrossRef195
Kathleen Conroy, Susan L. Rosenthal, Gregory D. Zimet, Yan Jin, David I. Bernstein, Susan Glynn, Jessica A. Kahn. (2009) Human Papillomavirus Vaccine Uptake, Predictors of Vaccination, and Self-Reported Barriers to Vaccination. Journal of Women's Health 18:10, 1679-1686
CrossRef196
Lidia Rosi Medeiros, Daniela Dornelles Rosa, Maria Inês da Rosa, Mary Clarisse Bozzetti, Roselaine Ruviaro Zanini. (2009) Efficacy of Human Papillomavirus Vaccines. International Journal of Gynecological Cancer 19:7, 1166-1176
CrossRef197
Paul K.S. Chan, Wendy C.S. Ho, Mei-Yung Yu, Wai-Mei Pong, Alexander C.L. Chan, Amanda K.C. Chan, Tak-Hong Cheung, Martin C.S. Wong, Ka-Fai To, Ho-Keung Ng. (2009) Distribution of human papillomavirus types in cervical cancers in Hong Kong: Current situation and changes over the last decades. International Journal of Cancer 125:7, 1671-1677
CrossRef198
Robin Biellik, Carol Levin, Emmanuel Mugisha, D. Scott LaMontagne, Allison Bingham, Satish Kaipilyawar, Sanjay Gandhi. (2009) Health systems and immunization financing for human papillomavirus vaccine introduction in low-resource settings. Vaccine 27:44, 6203-6209
CrossRef199
S Majewski, FX Bosch, J. Dillner, O-E Iversen, SK Kjaer, N Muñoz, S-E Olsson, J Paavonen, K Sigurdsson, J Bryan, MT Esser, K Giacoletti, M James, F Taddeo, S Vuocolo, E Barr. (2009) The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. Journal of the European Academy of Dermatology and Venereology 23:10, 1147-1155
CrossRef200
Katherine A. Hild-Mosley, Dipti M. Patel, Stephen Markwell, L. Stewart Massad. (2009) Knowledge of Cervical Cancer Screening, Human Papillomavirus, and HPV Vaccine Among Midwestern Gynecology Patients. Journal of Lower Genital Tract Disease 13:4, 200-206
CrossRef201
Lara C. Weinstein, Edward M. Buchanan, Christina Hillson, Christopher V. Chambers. (2009) Screening and Prevention: Cervical Cancer. Primary Care: Clinics in Office Practice 36:3, 559-574
CrossRef202
Archana Monie, Shaw-Wei D Tsen, Chien-Fu Hung, T-C Wu. (2009) Therapeutic HPV DNA vaccines. Expert Review of Vaccines 8:9, 1221-1235
CrossRef203
Ali Rowhani-Rahbar, Constance Mao, James P. Hughes, Frances B. Alvarez, Janine T. Bryan, Stephen E. Hawes, Noel S. Weiss, Laura A. Koutsky. (2009) Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 27:41, 5612-5619
CrossRef204
Lisandro Colantonio, Jorge A. Gómez, Nadia Demarteau, Baudouin Standaert, Andrés Pichón-Rivière, Federico Augustovski. (2009) Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine 27:40, 5519-5529
CrossRef205
Marco Rusnati, Elisa Vicenzi, Manuela Donalisio, Pasqua Oreste, Santo Landolfo, David Lembo. (2009) Sulfated K5 Escherichia coli polysaccharide derivatives: A novel class of candidate antiviral microbicides. Pharmacology & Therapeutics 123:3, 310-322
CrossRef206
Amanda F. Dempsey, Leah M. Abraham, Vanessa Dalton, Mack Ruffin. (2009) Understanding the Reasons Why Mothers Do or Do Not Have Their Adolescent Daughters Vaccinated Against Human Papillomavirus. Annals of Epidemiology 19:8, 531-538
CrossRef207
Philip E. Castle, Barbara Fetterman, Israh Akhtar, Mujtaba Husain, Michael A. Gold, Richard Guido, Andrew G. Glass, Walter Kinney. (2009) Age-appropriate use of human papillomavirus vaccines in the U.S.. Gynecologic Oncology 114:2, 365-369
CrossRef208
W. David Hager. (2009) Human Papilloma Virus Infection and Prevention in the Adolescent Population. Journal of Pediatric and Adolescent Gynecology 22:4, 197-204
CrossRef209
Vicente Madrid-Marina, Kirvis Torres-Poveda, Gabriela López-Toledo, Alejandro García-Carrancá. (2009) Advantages and Disadvantages of Current Prophylactic Vaccines Against HPV. Archives of Medical Research 40:6, 471-477
CrossRef210
Eduardo Lazcano-Ponce, Gonzalo Pérez, Aurelio Cruz-Valdez, Laura Zamilpa, Carlos Aranda-Flores, Pilar Hernández-Nevarez, Jose Luis Viramontes, Joaquín Salgado-Hernández, Margaret James, Shuang Lu, Carlos Sattler, Richard M. Haupt, Mauricio Hernández-Avila. (2009) Impact of a Quadrivalent HPV6/11/16/18 Vaccine in Mexican Women: Public Health Implications for the Region. Archives of Medical Research 40:6, 514-524
CrossRef211
Kahn, Jessica A., . (2009) HPV Vaccination for the Prevention of Cervical Intraepithelial Neoplasia. New England Journal of Medicine 361:3, 271-278
Full Text212
Ann M. Bode, Zigang Dong. (2009) Cancer prevention research — then and now. Nature Reviews Cancer 9:7, 508-516
CrossRef213
Elamin H. Elbasha, Erik J. Dasbach, Ralph P. Insinga, Richard M. Haupt, Eliav Barr. (2009) Age-Based Programs for Vaccination against HPV. Value in Health 12:5, 697-707
CrossRef214
Mamiko Onuki, Koji Matsumoto, Toyomi Satoh, Akinori Oki, Satoshi Okada, Takeo Minaguchi, Hiroyuki Ochi, Sari Nakao, Katsumi Someya, Naoki Yamada, Hiromi Hamada, Hiroyuki Yoshikawa. (2009) Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer. Cancer Science 100:7, 1312-1316
CrossRef215
Joslyn W. Fisher, Susan I. Brundage. (2009) The Challenge of Eliminating Cervical Cancer in the United States: A Story of Politics, Prudishness, and Prevention. Women & Health 49:2-3, 246-261
CrossRef216
Elisabeth Barthell, Linn Woelber, Karin Hellner, Birka Camerer, Friederike Gieseking, Maik Hauschild, Ioannis Mylonas, Klaus Friese, Heather L. Sings, Radha Railkar, Christine Gause, Eliav Barr. (2009) Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine. Archives of Gynecology and Obstetrics 279:6, 803-807
CrossRef217
Sun-Kuie TAY, Yeng-Kwang TAY. (2009) The prevalence and significance of high-risk human papillomavirus DNA test in southern Malaysia and Singapore. Australian and New Zealand Journal of Obstetrics and Gynaecology 49:3, 323-327
CrossRef218
Nubia Muñoz, Ricardo Manalastas, Punee Pitisuttithum, Damrong Tresukosol, Joseph Monsonego, Kevin Ault, Christine Clavel, Joaquin Luna, Evan Myers, Sara Hood, Oliver Bautista, Janine Bryan, Frank J Taddeo, Mark T Esser, Scott Vuocolo, Richard M Haupt, Eliav Barr, Alfred Saah. (2009) Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. The Lancet 373:9679, 1949-1957
CrossRef219
Mark H Einstein, John T Schiller, Raphael P Viscidi, Howard D Strickler, Pierre Coursaget, Tina Tan, Neal Halsey, David Jenkins. (2009) Clinician's guide to human papillomavirus immunology: knowns and unknowns. The Lancet Infectious Diseases 9:6, 347-356
CrossRef220
Jacob Bornstein. (2009) The HPV Vaccines—Which to Prefer?. Obstetrical & Gynecological Survey 64:5, 345-350
CrossRef221
Kathryn A Gold, Edward S Kim. (2009) Role of molecular markers and gene profiling in head and neck cancers. Current Opinion in Oncology 21:3, 206-211
CrossRef222
Marinko Dobec, Fridolin Bannwart, Franz Kaeppeli, Pascal Cassinotti. (2009) Automation of the linear array HPV genotyping test and its application for routine typing of human papillomaviruses in cervical specimens of women without cytological abnormalities in Switzerland. Journal of Clinical Virology 45:1, 23-27
CrossRef223
H.M. Hepburn, A.M. Kaufmann. (2009) Nobelpreis für die Impfung gegen Zervixkrebs. Der Internist 50:5, 617-626
CrossRef224
Laura A.V. Marlow, Alice S. Forster, Jane Wardle, Jo Waller. (2009) Mothers' and Adolescents' Beliefs about Risk Compensation following HPV Vaccination. Journal of Adolescent Health 44:5, 446-451
CrossRef225
F.S. Mennini, S. Costa, G. Favato, M. Picardo. (2009) Anti-HPV vaccination: A review of recent economic data for Italy. Vaccine 27, A54-A61
CrossRef226
Paolo Bonanni, Sara Boccalini, Angela Bechini. (2009) Efficacy, duration of immunity and cross protection after HPV vaccination: A review of the evidence. Vaccine 27, A46-A53
CrossRef227
Laura Koutsky. (2009) The Epidemiology behind the HPV Vaccine Discovery. Annals of Epidemiology 19:4, 239-244
CrossRef228
Alison Fiander. (2009) Prophylactic human papillomavirus vaccination update. The Obstetrician & Gynaecologist 11:2, 133-135
CrossRef229
Michael Dougan, Glenn Dranoff. (2009) Immune Therapy for Cancer. Annual Review of Immunology 27:1, 83-117
CrossRef230
Germaine Wong, Kirsten Howard, Angela Webster, Jeremy R. Chapman, Jonathan C. Craig. (2009) The Health and Economic Impact of Cervical Cancer Screening and Human Papillomavirus Vaccination in Kidney Transplant Recipients. Transplantation 87:7, 1078-1091
CrossRef231
Norma Martinez Rogers, Adelita G. Cantu. (2009) The Nurse’s Role in the Prevention of Cervical Cancer Among Underserved and Minority Populations. Journal of Community Health 34:2, 135-143
CrossRef232
Nancy Thiry, Chris De Laet, Frank Hulstaert, Mattias Neyt, Michel Huybrechts, Irina Cleemput. (2009) Cost-effectiveness of human papillomavirus vaccination in Belgium: Do not forget about cervical cancer screening. International Journal of Technology Assessment in Health Care 25:02, 161
CrossRef233
Peter Hillemanns, Karl Ulrich Petry, Nathalie Largeron, Ruth McAllister, Keith Tolley, Katharina Büsch. (2009) Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany. Journal of Public Health 17:2, 77-86
CrossRef234
Amy A. Hakim, Tri A. Dinh. (2009) Worldwide Impact of the Human Papillomavirus Vaccine. Current Treatment Options in Oncology 10:1-2, 44-53
CrossRef235
Xianding Wang, Jing Zhuang, Zhiyuan Xie, Mingyuan Li, Yiping Lu. (2009) Animal models for human papillomavirus-associated cervical pathogenesis. Reviews in Medical Microbiology 20:2, 33-40
CrossRef236
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Goldstein, Mark A., Goodman, Annekathryn, del Carmen, Marcela G., Wilbur, David C., . (2009) Case 10-2009. New England Journal of Medicine 360:13, 1337-1344
Full Text237
L. E. Markowitz, E. R. Unger, M. Saraiya. (2009) Primary and Secondary Prevention of Cervical Cancer--Opportunities and Challenges. JNCI Journal of the National Cancer Institute 101:7, 439-440
CrossRef238
Ioannis N. Mammas, George Sourvinos, Demetrios A. Spandidos. (2009) Human papilloma virus (HPV) infection in children and adolescents. European Journal of Pediatrics 168:3, 267-273
CrossRef239
Brenda L. Bartlett, Stephen K. Tyring. (2009) Safety and efficacy of vaccines. Dermatologic Therapy 22:2, 97-103
CrossRef240
L. Denny. (2009) The burden of disease associated with infection with human papillomavirus. African Journal of Urology 15:1, 1-6
CrossRef241
Anita Satyaprakash, Rosella Creed, Parisa Ravanfar, Natalia Mendoza. (2009) Human papillomavirus vaccines. Dermatologic Therapy 22:2, 150-157
CrossRef242
William N. William, John V. Heymach, Edward S. Kim, Scott M. Lippman. (2009) Molecular targets for cancer chemoprevention. Nature Reviews Drug Discovery 8:3, 213-225
CrossRef243
Veerle M.H. Coupé, Joost van Ginkel, Hester E. de Melker, Peter J.F. Snijders, Chris J.L.M. Meijer, Johannes Berkhof. (2009) HPV16/18 vaccination to prevent cervical cancer in The Netherlands: Model-based cost-effectiveness. International Journal of Cancer 124:4, 970-978
CrossRef244
F.S. Mennini, P. Giorgi Rossi, F. Palazzo, N. Largeron. (2009) Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecologic Oncology 112:2, 370-376
CrossRef245
Ming-Shien Yen, Shan-Lin You, Nicole Ferko, Donna Debicki, Yi-Chen Chen, Cheng-Yang Chou. (2009) Estimating the Long-Term Clinical Impact of Cervical Cancer Vaccination in Taiwan. International Journal of Gynecological Cancer 19:2, 281-288
CrossRef246
Chris J.L.M. Meijer, Daniëlle A.M. Heideman, Hans Berkhof, Peter J.F. Snijders. (2009) Prevention of cervical cancer: Where immunology meets diagnostics. Immunology Letters 122:2, 126-127
CrossRef247
Hal B Jenson. (2009) Human papillomavirus vaccine: a paradigm shift for pediatricians. Current Opinion in Pediatrics 21:1, 112-121
CrossRef248
Alan L. Schwartz, Aaron Ciechanover. (2009) Targeting Proteins for Destruction by the Ubiquitin System: Implications for Human Pathobiology. Annual Review of Pharmacology and Toxicology 49:1, 73-96
CrossRef249
U. Ayazpoor. (2009) HNO-Update-Seminar. HNO 57:2, 178-180
CrossRef250
Mary A. Gerend, Jessica Barley. (2009) Human Papillomavirus Vaccine Acceptability Among Young Adult Men. Sexually Transmitted Diseases 36:1, 58-62
CrossRef251
Lieven Annemans, Vanessa Rémy, James Oyee, Nathalie Largeron. (2009) Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium. PharmacoEconomics 27:3, 231-245
CrossRef252
A.E. Albers, B. Sinikovic, A.V. Banko, S. Jovanovic, A.M. Kaufmann. (2009) Developments in therapeutic human papillomavirus vaccination. Acta chirurgica iugoslavica 56:3, 29-37
CrossRef253
Wing Leung. (2009) Immunotherapy in Acute Leukemia. Seminars in Hematology 46:1, 89-99
CrossRef254
Silvia Franceschi, Hugo De Vuyst. (2009) Human papillomavirus vaccines and anal carcinoma. Current Opinion in HIV and AIDS 4:1, 57-63
CrossRef255
Mi-Kyung Kim, Jae Hong No, Yong-Sang Song. (2009) Human Papillomavirus Vaccine. Journal of the Korean Medical Association 52:12, 1180
CrossRef256
Tino F. Schwarz, Marek Spaczynski, Achim Schneider, Jacek Wysocki, Andrzej Galaj, Pamela Perona, Sylviane Poncelet, Toufik Zahaf, Karin Hardt, Dominique Descamps, Gary Dubin. (2009) Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years. Vaccine 27:4, 581-587
CrossRef257
Kidong Kim, Sang-Young Ryu. (2009) Major clinical research advances in gynecologic cancer 2009. Journal of Gynecologic Oncology 20:4, 203
CrossRef258
M. Martín Angulo, B. Martínez-Amores Martínez, F. Navarro Expósito, M. Álvarez-Mon Soto. (2009) Cáncer de cérvix. Medicine - Programa de Formación Médica Continuada Acreditado 10:24, 1606-1612
CrossRef259
Janis M. Taube, Betty Kamira, Mahnaz Motevalli, Clemensia Nakabiito, Robert Lukande, Deidra P. Kelly, Yener S. Erozan, Patti E. Gravitt, Megan E. Buresh, Francis Mmiro, Danstan Bagenda, Laura A. Guay, J. Brooks Jackson. (2009) Human papillomavirus prevalence and cytopathology correlation in young Ugandan women using a low-cost liquid-based Pap preparation. Diagnostic CytopathologyNA-NA
CrossRef260
Tiina Petäjä, Heli Keränen, Tiina Karppa, Anna Kawa, Sirkku Lantela, Mari Siitari-Mattila, Helena Levänen, Tuomas Tocklin, Olivier Godeaux, Matti Lehtinen, Gary Dubin. (2009) Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10–18 Years. Journal of Adolescent Health 44:1, 33-40
CrossRef261
Aljosa Mandic. (2009) Prophylactic HPV vaccines. Archive of oncology 17:3-4, 68-71
CrossRef262
M. Stanley. (2008) HPV vaccines: are they the answer?. British Medical Bulletin 88:1, 59-74
CrossRef263
L. David Wise, Jayanthi J. Wolf, Catherine V. Kaplanski, Cindy J. Pauley, Brian J. Ledwith. (2008) Lack of effects on fertility and developmental toxicity of a quadrivalent HPV vaccine in Sprague-Dawley rats. Birth Defects Research Part B: Developmental and Reproductive Toxicology 83:6, 561-572
CrossRef264
Kimiko L. Ishibashi, Joy Koopmans, Farr A. Curlin, Kenneth A. Alexander, Lainie Friedman Ross. (2008) Pediatricians are More Supportive of the Human Papillomavirus Vaccine than the General Public. Southern Medical Journal 101:12, 1216-1221
CrossRef265
Elmar A. Joura, Susanne K. Kjaer, Cosette M. Wheeler, Kristján Sigurdsson, Ole-Erik Iversen, Mauricio Hernandez-Avila, Gonzalo Perez, Darron R. Brown, Laura A. Koutsky, Eng Hseon Tay, Patricia García, Kevin A. Ault, Suzanne M. Garland, Sepp Leodolter, Sven-Eric Olsson, Grace W.K. Tang, Daron G. Ferris, Jorma Paavonen, Matti Lehtinen, Marc Steben, Xavier Bosch, Joakim Dillner, Robert J. Kurman, Slawomir Majewski, Nubia Muñoz, Evan R. Myers, Luisa L. Villa, Frank J. Taddeo, Christine Roberts, Amha Tadesse, Janine Bryan, Lisa C. Lupinacci, Katherine E.D. Giacoletti, Shuang Lu, Scott Vuocolo, Teresa M. Hesley, Richard M. Haupt, Eliav Barr. (2008) HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26:52, 6844-6851
CrossRef266
Ana Oaknin, M. Pilar Barretina. (2008) Human papillomavirus vaccine and cervical cancer prevention. Clinical and Translational Oncology 10:12, 804-811
CrossRef267
Alan G. Waxman. (2008) Cervical Cancer Screening in the Early Postvaccine Era. Obstetrics and Gynecology Clinics of North America 35:4, 537-548
CrossRef268
Thomas Q Gallagher, Craig S Derkay. (2008) Recurrent respiratory papillomatosis: update 2008. Current Opinion in Otolaryngology & Head and Neck Surgery 16:6, 536-542
CrossRef269
Ehab A. Molokhia, Allen Perkins. (2008) Preventing Cancer. Primary Care: Clinics in Office Practice 35:4, 609-623
CrossRef270
Ralph P. Insinga, Erik J. Dasbach, Shannon E. Allen, George W. Carides, Evan R. Myers. (2008) Reductions in Human Papillomavirus-Disease Resource Use and Costs with Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccination: The FUTURE Study Economic Evaluation. Value in Health 11:7, 1022-1032
CrossRef271
Linda J Rogers, Lois J Eva, David Michael Luesley. (2008) Vaccines against cervical cancer. Current Opinion in Internal Medicine 7:6, 633-637
CrossRef272
Eileen F. Dunne, S. Deblina Datta, Lauri E. Markowitz. (2008) A review of prophylactic human papillomavirus vaccines: Recommendations and monitoring in the US. Cancer 113:S10, 2995-3003
CrossRef273
Sonja Textor, Matthias Dürst, Lars Jansen, Rosita Accardi, Massimo Tommasino, Marcus J. Trunk, Angel Porgador, Carsten Watzl, Lutz Gissmann, Adelheid Cerwenka. (2008) Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. International Journal of Cancer 123:10, 2343-2353
CrossRef274
Maura L. Gillison, Anil K. Chaturvedi, Douglas R. Lowy. (2008) HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 113:S10, 3036-3046
CrossRef275
Philip E. Castle, Diane Solomon, Debbie Saslow, Mark Schiffman. (2008) Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States. Cancer 113:S10, 3031-3035
CrossRef276
A. C. Webster, G. Wong, J. C. Craig, J. R. Chapman. (2008) Managing Cancer Risk and Decision Making After Kidney Transplantation. American Journal of Transplantation 8:11, 2185-2191
CrossRef277
Carolyn D. Runowicz, Stephanie Garozzo. (2008) Human papillomavirus testing for primary cervical cancer screening. Current Oncology Reports 10:6, 533-537
CrossRef278
César Alameda González, Antonio de Lorenzo-Cáceres Ascanio. (2008) Respuesta de los autores. Atención Primaria 40:11, 585-586
CrossRef279
Lucia Six, Sepp Leodolter, Heather L. Sings, Eliav Barr, Richard Haupt, Elmar A. Joura. (2008) Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women – baseline data of a phase III vaccine trial. Wiener klinische Wochenschrift 120:21-22, 666-671
CrossRef280
Silvia de Sanjosé, Laia Alemany, Xavier Castellsagué, F Xavier Bosch. (2008) Human papillomavirus vaccines and vaccine implementation. Women's Health 4:6, 595-604
CrossRef281
M. Merito, N. Largeron, C. Cohet, L. Timelli, F. Boselli, A. Matteelli, L. Naldi, G. Vittori. (2008) Treatment patterns and associated costs for genital warts in Italy. Current Medical Research and Opinion 24:11, 3175-3183
CrossRef282
X. Castellsague, C. Cohet, L. M Puig-Tintore, L. O. Acebes, J. Salinas, M. S. Martin, L. Breitscheidel, V. Remy. (2008) Epidemiology and cost of treatment of genital warts in Spain. The European Journal of Public Health 19:1, 106-110
CrossRef283
Susanne K. Kjaer, Gabrielle Breugelmans, Christian Munk, Jette Junge, Michael Watson, Thomas Iftner. (2008) Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. International Journal of Cancer 123:8, 1864-1870
CrossRef284
Megan A. Smith, Karen Canfell, Julia M.L. Brotherton, Jie-Bin Lew, Ruanne V. Barnabas. (2008) The predicted impact of vaccination on human papillomavirus infections in Australia. International Journal of Cancer 123:8, 1854-1863
CrossRef285
Douglas R. Lowy, Diane Solomon, Allan Hildesheim, John T. Schiller, Mark Schiffman. (2008) Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer 113:S7, 1980-1993
CrossRef286
Anna-Barbara Moscicki. (2008) HPV Vaccines: Today and in the Future. Journal of Adolescent Health 43:4, S26-S40
CrossRef287
Jennifer S. Smith, Amy Melendy, Rashida K. Rana, Jeanne M. Pimenta. (2008) Age-Specific Prevalence of Infection with Human Papillomavirus in Females: A Global Review. Journal of Adolescent Health 43:4, S5.e1-S5.e62
CrossRef288
Karen K. Smith-McCune. (2008) Human papillomavirus vaccine efficacy: Aligning expectations with reality. Gynecologic Oncology 111:1, 1-2
CrossRef289
Birger Trollfors. (2008) Human papillomavirus vaccines: an outsider’s point of view. Expert Review of Vaccines 7:8, 1131-1133
CrossRef290
Daron G. Ferris, Jennifer L. Waller, Jeremiah Miller, Pratik Patel, Lanier Jackson, George A. Price, Courtesia Wilson. (2008) Men's Attitudes Toward Receiving the Human Papillomavirus Vaccine. Journal of Lower Genital Tract Disease 12:4, 276-281
CrossRef291
Cara Usher, Lesley Tilson, Jens Olsen, Martin Jepsen, Cathal Walsh, Michael Barry. (2008) Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine 26:44, 5654-5661
CrossRef292
Saad Ghazal-Aswad. (2008) Cervical Cancer Prevention in the Human Papilloma Virus Vaccine Era. Annals of the New York Academy of Sciences 1138:1, 253-256
CrossRef293
Linda J Rogers, Lois J Eva, David Michael Luesley. (2008) Vaccines against cervical cancer. Current Opinion in Oncology 20:5, 570-574
CrossRef294
Eugenio Suárez, Jennifer S. Smith, F. Xavier Bosch, Pekka Nieminen, Chien-Jen Chen, Saku Torvinen, Nadia Demarteau, Baudouin Standaert. (2008) Cost-effectiveness of vaccination against cervical cancer: A multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine 26, F29-F45
CrossRef295
E.H. Tay, S. Garland, G. Tang, T. Nolan, L.-M. Huang, L. Orloski, S. Lu, E. Barr. (2008) Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific region. International Journal of Gynecology & Obstetrics 102:3, 275-283
CrossRef296
Nicole Ferko, Maarten Postma, Steve Gallivan, Denise Kruzikas, Michael Drummond. (2008) Evolution of the health economics of cervical cancer vaccination. Vaccine 26, F3-F15
CrossRef297
Alan G. Waxman, Meggan M. Zsemlye. (2008) Preventing Cervical Cancer: The Pap Test and the HPV Vaccine. Medical Clinics of North America 92:5, 1059-1082
CrossRef298
KEVIN A. AULT. (2008) Human Papillomavirus Vaccines: An Update for Gynecologists. Clinical Obstetrics and Gynecology 51:3, 527-532
CrossRef299
José-María Bayas, Laura Costas, Amparo Muñoz. (2008) Cervical cancer vaccination indications, efficacy, and side effects. Gynecologic Oncology 110:3, S11-S14
CrossRef300
Donna Debicki, Nicole Ferko, Nadia Demarteau, Steve Gallivan, Chris Bauch, Andrea Anonychuk, Lorenzo Mantovani, Stefano Capri, Cheng-Yang Chou, Baudouin Standaert, Lieven Annemans. (2008) Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine 26, F16-F28
CrossRef301
S. KANG, K.H. KIM, Y.T. KIM, Y.T. KIM, J.H. KIM, Y.S. SONG, S.H. SHIN, H.S. RYU, J.W. HAN, J.H. KANG, S.Y. PARK. (2008) Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects. International Journal of Gynecological Cancer 18:5, 1013-1019
CrossRef302
T. MATSUKURA, M. SUGASE. (2008) Pitfalls in the epidemiologic classification of human papillomavirus types associated with cervical cancer using polymerase chain reaction: driver and passenger. International Journal of Gynecological Cancer 18:5, 1042-1050
CrossRef303
Kim, Jane J., Goldie, Sue J., . (2008) Health and Economic Implications of HPV Vaccination in the United States. New England Journal of Medicine 359:8, 821-832
Full Text304
Haug, Charlotte J., . (2008) Human Papillomavirus Vaccination — Reasons for Caution. New England Journal of Medicine 359:8, 861-862
Full Text305
Claudia Istrate, Jorma Hinkula, Annie Charpilienne, Didier Poncet, Jean Cohen, Lennart Svensson, Kari Johansen. (2008) Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice. Vaccine 26:35, 4594-4601
CrossRef306
Keerti V. Shah. (2008) Asia Pacific: Cervical Cancer Screening and Human Papillomavirus Vaccination Policy and Delivery. Vaccine 26, iii-iv
CrossRef307
John T. Schiller, Xavier Castellsagué, Luisa L. Villa, Allan Hildesheim. (2008) An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26, K53-K61
CrossRef308
Suzanne M. Garland, Jack Cuzick, Efren J. Domingo, Sue J. Goldie, Young-Tak Kim, Ryo Konno, D. Maxwell Parkin, You-Lin Qiao, Rengaswamy Sankaranarayanan, Peter L. Stern, Sun Kuie Tay, F. Xavier Bosch. (2008) Recommendations for Cervical Cancer Prevention in Asia Pacific. Vaccine 26, M89-M98
CrossRef309
M. Stanley. (2008) Human Papillomavirus Vaccines versus Cervical Cancer Screening. Clinical Oncology 20:6, 388-394
CrossRef310
Marissa B Wilck, Lindsey R Baden. (2008) Vaccination after stem cell transplant: a review of recent developments and implications for current practice. Current Opinion in Infectious Diseases 21:4, 399-408
CrossRef311
Pierre Damme, Sergio Pecorelli, Elmar A. Joura. (2008) The introduction of policies for human papillomavirus vaccination in Europe. Journal of Public Health 16:4, 291-298
CrossRef312
Jean-Luc Prétet, Anne-Carole Jacquard, Maëlle Saunier, Christine Clavel, Roger Dachez, Jean Gondry, Pierre Pradat, Benoît Soubeyrand, Yann Leocmach, Christiane Mougin, Didier Riethmuller. (2008) Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and comparison with CIN2/3 and invasive cervical cancer. Gynecologic Oncology 110:2, 179-184
CrossRef313
DAM Heideman, PJF Snijders, J Berkhof, RHM Verheijen, TJM Helmerhorst, CJLM Meijer. (2008) Vaccination against HPV: indications for women and the impact on the cervical screening programme. BJOG: An International Journal of Obstetrics & Gynaecology 115:8, 938-946
CrossRef314
Amrita Krishnan, Alexandra M Levine. (2008) Malignancies in women with HIV infection. Women's Health 4:4, 357-368
CrossRef315
Sue J. Goldie, Meredith O'Shea, Nicole Gastineau Campos, Mireia Diaz, Steven Sweet, Sun-Young Kim. (2008) Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 26:32, 4080-4093
CrossRef316
Troy J. Kemp, Alfonso García-Piñeres, Roni T. Falk, Sylviane Poncelet, Francis Dessy, Sandra L. Giannini, Ana Cecilia Rodriguez, Carolina Porras, Rolando Herrero, Allan Hildesheim, Ligia A. Pinto. (2008) Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 26:29-30, 3608-3616
CrossRef317
Bhuvanesh Singh. (2008) Molecular pathogenesis of head and neck cancers. Journal of Surgical Oncology 97:8, 634-639
CrossRef318
RICHARD GUIDO. (2008) Human Papillomavirus and Cervical Disease in Adolescents. Clinical Obstetrics and Gynecology 51:2, 290-305
CrossRef319
Anthony T. Newall, Julia M. L. Brotherton, Helen E. Quinn, Peter B. McIntyre, Josephine Backhouse, Lynn Gilbert, Mark T. Esser, Joanne Erick, Janine Bryan, Neil Formica, C. Raina MacIntyre. (2008) Population Seroprevalence of Human Papillomavirus Types 6, 11, 16, and 18 in Men, Women, and Children in Australia. Clinical Infectious Diseases 46:11, 1647-1655
CrossRef320
Warren R. Heymann. (2008) The human papillomavirus vaccine. Journal of the American Academy of Dermatology 58:6, 1047-1048
CrossRef321
Jorma Paavonen. (2008) Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials. Current Medical Research and Opinion 24:6, 1623-1634
CrossRef322
Pere Fusté, Xavier Santamaría, Ramon Carreras. (2008) Nuevas estrategias terapéuticas para las lesiones anogenitales relacionadas con el virus del papiloma humano en pacientes con infección por el VIH: tratamiento antirretroviral de gran actividad y vacunas anti-VPH. Medicina Clínica 131:1, 30-34
CrossRef323
Christine M. Huang. (2008) Human Papillomavirus and Vaccination. Mayo Clinic Proceedings 83:6, 701-707
CrossRef324
P. E. Castle. (2008) Invited Commentary: Is Monitoring of Human Papillomavirus Infection for Viral Persistence Ready for Use in Cervical Cancer Screening?. American Journal of Epidemiology 168:2, 138-144
CrossRef325
Lynette Denny. (2008) Prevention of cervical cancer in developing countries. Therapy 5:3, 329-338
CrossRef326
Warner K. Huh, Richard B.S. Roden. (2008) The future of vaccines for cervical cancer. Gynecologic Oncology 109:2, S48-S56
CrossRef327
F Xavier Bosch, Silvia de Sanjosé, Xavier Castellsagué. (2008) Evaluating the potential benefits of universal worldwide human papillomavirus vaccination. Therapy 5:3, 305-312
CrossRef328
Joel Palefsky. (2008) Human papillomavirus and anal neoplasia. Current HIV/AIDS Reports 5:2, 78-85
CrossRef329
Levi S. Downs, Jennifer S. Smith, Isabel Scarinci, Lisa Flowers, Groesbeck Parham. (2008) The disparity of cervical cancer in diverse populations. Gynecologic Oncology 109:2, S22-S30
CrossRef330
M Lehtinen, KM French, J Dillner, J Paavonen, G Garnett. (2008) Sound implementation of human papillomavirus vaccination as a community-randomized trial. Therapy 5:3, 289-294
CrossRef331
Evan R. Myers. (2008) The economic impact of HPV vaccines: not just cervical cancer. American Journal of Obstetrics and Gynecology 198:5, 487-488
CrossRef332
Gabi U Dachs, Margaret J Currie, Fiona McKenzie, Mona Jeffreys, Brian Cox, Sunia Foliaki, Loïc Le Marchand, Bridget A Robinson. (2008) Cancer disparities in indigenous Polynesian populations: Māori, Native Hawaiians, and Pacific people. The Lancet Oncology 9:5, 473-484
CrossRef333
Jorma Paavonen. (2008) Efficacy of a prophylactic human papillomavirus vaccine against high-grade vulval and vaginal intraepithelial neoplasia. Therapy 5:3, 325-328
CrossRef334
Thomas J. Herzog, Warner K. Huh, Levi S. Downs, Jennifer S. Smith, Bradley J. Monk. (2008) Initial lessons learned in HPV vaccination. Gynecologic Oncology 109:2, S4-S11
CrossRef335
Diane M Harper. (2008) Prophylactic human papillomavirus vaccines to prevent cervical cancer: review of the Phase II and III trials. Therapy 5:3, 313-324
CrossRef336
Jason E. Frangos, Christina N. Alavian, Alexa B. Kimball. (2008) Acne and oral contraceptives: Update on women's health screening guidelines. Journal of the American Academy of Dermatology 58:5, 781-786
CrossRef337
Thomas C. Wright, Warner K. Huh, Bradley J. Monk, Jennifer S. Smith, Kevin Ault, Thomas J. Herzog. (2008) Age considerations when vaccinating against HPV. Gynecologic Oncology 109:2, S40-S47
CrossRef338
Shelley Miksis. (2008) A Review of the Evidence Comparing the Human Papillomavirus Vaccine Versus Condoms in the Prevention of Human Papillomavirus Infections. Journal of Obstetric, Gynecologic, & Neonatal Nursing 37:3, 329-337
CrossRef339
Thomas D. Szucs, Nathalie Largeron, Konstantin J. Dedes, Rachid Rafia, Stève Bénard. (2008) Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Current Medical Research and Opinion 24:5, 1473-1483
CrossRef340
Karen J Nishida, J Matthew Pearson, Leo B Twiggs. (2008) Cross-protection from human papillomavirus 16/18 against types 45 and 31: fact or fancy?. Therapy 5:3, 265-268
CrossRef341
Mark H. Einstein. (2008) Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines. Cancer Immunology, Immunotherapy 57:4, 443-451
CrossRef342
David M. Jaspan, Charles J. Dunton, Traci L. Cook. (2008) Acceptance of Human Papillomavirus Vaccine by Gynecologists in an Urban Setting. Journal of Lower Genital Tract Disease 12:2, 118-121
CrossRef343
PM Parikh, R Bharath, HB Tongaonkar. 2008. Cervical cancer. , 121-126.
CrossRef344
Michael N. Starnbach, Nadia R. Roan. (2008) Conquering sexually transmitted diseases. Nature Reviews Immunology 8:4, 313-317
CrossRef345
César Alameda González, Antonio de Lorenzo-Cáceres Ascanio. (2008) Vacuna contra el papilomavirus humano: actitud ante una consulta sobre una novedad terapéutica. Atención Primaria 40:4, 205-208
CrossRef346
Gonzalo Perez, Eduardo Lazcano-Ponce, Mauricio Hernandez-Avila, Patricia J. García, Nubia Muñoz, Luisa L. Villa, Janine Bryan, Frank J. Taddeo, Shuang Lu, Mark T. Esser, Scott Vuocolo, Carlos Sattler, Eliav Barr. (2008) Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. International Journal of Cancer 122:6, 1311-1318
CrossRef347
Peter V. Chin‐Hong. (2008) Cutting Human Papillomavirus Infection in Men. The Journal of Infectious Diseases 197:6, 781-783
CrossRef348
J. D. Goldhaber-Fiebert, N. K. Stout, J. A. Salomon, K. M. Kuntz, S. J. Goldie. (2008) Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination. JNCI Journal of the National Cancer Institute 100:5, 308-320
CrossRef349
Eliav Barr, Christine K. Gause, Oliver M. Bautista, Radha A. Railkar, Lisa C. Lupinacci, Ralph P. Insinga, Heather L. Sings, Richard M. Haupt. (2008) Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. American Journal of Obstetrics and Gynecology 198:3, 261.e1-261.e11
CrossRef350
Michael L. Landrum, Matthew J. Dolan. (2008) Routine Vaccination in HIV-Infected Adults. Infectious Diseases in Clinical Practice 16:2, 85-93
CrossRef351
Bruce H Thiers. (2008) What's new in dermatologic therapy. Dermatologic Therapy 21:2, 142-149
CrossRef352
Amanda F. Dempsey, Gary L. Freed. (2008) Human Papillomavirus Vaccination: Expected Impacts and Unresolved Issues. The Journal of Pediatrics 152:3, 305-309
CrossRef353
J Matt Pearson, Richard S Feltman, Leo B Twiggs. (2008) Association of human papillomavirus with vulvar and vaginal intraepithelial disease: opportunities for prevention. Women's Health 4:2, 143-150
CrossRef354
J. Monsonego. (2008) The new challenges in the prevention of cervical cancer. Vaccine 26, A4-A6
CrossRef355
D. van Hamont, R. L. M. Bekkers, L. F. A. G. Massuger, W. J. G. Melchers. (2008) Detection, management, and follow-up of pre-malignant cervical lesions and the role for human papillomavirus. Reviews in Medical Virology 18:2, 117-132
CrossRef356
Silvia Franceschi, Gary M. Clifford. (2008) Fraction of cervical neoplasias due to human papillomavirus 16 and 18 in vaccine trials. International Journal of Cancer 122:3, 719-720
CrossRef357
Tara Lee Frenkl, Jeannette Potts. (2008) Sexually Transmitted Infections. Urologic Clinics of North America 35:1, 33-46
CrossRef358
Gregory D. Zimet, Marcia L. Shew, Jessica A. Kahn. (2008) Appropriate Use of Cervical Cancer Vaccine. Annual Review of Medicine 59:1, 223-236
CrossRef359
Annie J. Sasco. (2008) Cancer and globalization. Biomedicine & Pharmacotherapy 62:2, 110-121
CrossRef360
Shreya Kanodia, Diane M. Da Silva, W. Martin Kast. (2008) Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. International Journal of Cancer 122:2, 247-259
CrossRef361
F X Bosch, X Castellsagué, Matthay (Editors) K. (2008) HPV and cervical cancer: screening or vaccination?. British Journal of Cancer 98:1, 15-21
CrossRef362
Christine Bergeron, Nathalie Largeron, Ruth McAllister, Patrice Mathevet, Vanessa Remy. (2008) Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. International Journal of Technology Assessment in Health Care 24:01,
CrossRef363
B.H. Thiers. (2008) Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases. Yearbook of Dermatology and Dermatologic Surgery 2008, 148-149
CrossRef364
Kidong Kim, Jae Weon Kim, Soon-Beom Kang. (2008) Major clinical research advances in gynecologic cancer 2007. Korean Journal of Gynecologic Oncology 19:1, 1
CrossRef365
Xavier Castellsagué Piqué, F. Xavier Bosch José. (2008) Vacunas frente al virus del papiloma humano. Enfermedades Infecciosas y Microbiología Clínica 26, 65-77
CrossRef366
Cosette M. Wheeler, Oliver M. Bautista, Joanne E. Tomassini, Margaret Nelson, Carlos A. Sattler, Eliav Barr. (2008) Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 26:5, 686-696
CrossRef367
Philip E. Castle, Mario Sideri, Jose Jeronimo, Diane Solomon, Mark Schiffman. (2008) Risk Assessment to Guide the Prevention of Cervical Cancer. Journal of Lower Genital Tract Disease 12:1, 1-7
CrossRef368
Amanda Psyrri, Daniel DiMaio. (2008) Human papillomavirus in cervical and head-and-neck cancer. Nature Clinical Practice Oncology 5:1, 24-31
CrossRef369
B.H. Thiers. (2008) Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. Yearbook of Dermatology and Dermatologic Surgery 2008, 147-148
CrossRef370
Monika Hampl. (2008) Impfung gegen humane Papillomaviren. Eine neue Präventionsstrategie gegen Krebs. Pharmazie in unserer Zeit 37:1, 78-85
CrossRef371
Chris JLM Meijer, Johannes Berkhof, Daniëlle AM Heideman, Peter JF Snijders. (2008) Cervical cancer prevention: who should receive vaccination?. Nature Clinical Practice Oncology 5:1, 12-13
CrossRef372
Kidong Kim, Seok-Cheol Choi, Sang-Young Ryu, Jae Weon Kim, Soon-Beom Kang. (2008) Major clinical research advances in gynecologic cancer 2008. Journal of Gynecologic Oncology 19:4, 209
CrossRef373
Kristjan Sigurdsson, Frank J. Taddeo, Kristrun R. Benediktsdottir, Kristrun Olafsdottir, Helgi Sigvaldason, Kristjan Oddsson, Thorunn Rafnar. (2007) HPV genotypes in CIN 2-3 lesions and cervical cancer: A population-based study. International Journal of Cancer 121:12, 2682-2687
CrossRef374
C. Paul. (2007) Quoi de neuf en thérapeutique ?. Annales de Dermatologie et de Vénéréologie 134, 8S64-8S75
CrossRef375
Luisa Lina Villa. (2007) Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. International Journal of Infectious Diseases 11, S17-S25
CrossRef376
J. Sibilia. (2007) Quoi de neuf en médecine en 2007 ?. Annales de Dermatologie et de Vénéréologie 134, 8S24-8S35
CrossRef377
Allan Hildesheim, Rolando Herrero. (2007) Human Papillomavirus Vaccine Should Be Given before Sexual Debut for Maximum Benefit. The Journal of Infectious Diseases 196:10, 1431-1432
CrossRef378
(2007) Prophylactic Efficacy of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Women with Virological Evidence of HPV Infection. The Journal of Infectious Diseases 196:10, 1438-1446
CrossRef379
J J Kim, B Andres-Beck, S J Goldie. (2007) The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. British Journal of Cancer 97:9, 1322-1328
CrossRef380
Anna R. Giuliano. (2007) Human papillomavirus vaccination in males. Gynecologic Oncology 107:2, S24-S26
CrossRef381
Kathleen M. Vetter, Stacie E. Geller. (2007) Moving Forward: Human Papillomavirus Vaccination and the Prevention of Cervical Cancer. Journal of Women's Health 16:9, 1258-1268
CrossRef382
M. Stanley. (2007) Prevention strategies against the human papillomavirus: The effectiveness of vaccination. Gynecologic Oncology 107:2, S19-S23
CrossRef383
J. Weiß, M.W. Beckmann. (2007) Zur Therapie des Zervixkarzinoms. Der Gynäkologe 40:11, 903-907
CrossRef384
Kevin A. Ault. (2007) Long-term efficacy of human papillomavirus vaccination. Gynecologic Oncology 107:2, S27-S30
CrossRef385
C. Derancourt. (2007) Prophylaxie vaccinale de l’infection à papillomavirus humains. Annales de Dermatologie et de Vénéréologie 134:11, 882-885
CrossRef386
Maurie Markman. (2007) HPV Vaccination and the Prevention of Cervical Cancer: The Long Road Ahead. Journal of Women's Health 16:9, 1366-1367
CrossRef387
Claire-Anne Siegrist, Edwin M. Lewis, Juhani Eskola, Stephen J. W. Evans, Steven B. Black. (2007) Human Papilloma Virus Immunization in Adolescent and Young Adults. The Pediatric Infectious Disease Journal 26:11, 979-984
CrossRef388
Mayrand, Marie-Hélène, Duarte-Franco, Eliane, Rodrigues, Isabel, Walter, Stephen D., Hanley, James, Ferenczy, Alex, Ratnam, Sam, Coutlée, François, Franco, Eduardo L., . (2007) Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer. New England Journal of Medicine 357:16, 1579-1588
Full Text389
Philip E. Castle, Mario Sideri, Jose Jeronimo, Diane Solomon, Mark Schiffman. (2007) Risk assessment to guide the prevention of cervical cancer. American Journal of Obstetrics and Gynecology 197:4, 356.e1-356.e6
CrossRef390
(2007) Human Papillomavirus Vaccine. New England Journal of Medicine 357:11, 1154-1156
Full Text391
Heather B Jaspan, Willem A Hanekom. (2007) Immunology of infants through adolescents: responses to emulate for HIV vaccines. Current Opinion in HIV and AIDS 2:5, 391-398
CrossRef392
Marc Arbyn. (2007) Effects of quadrivalent human papillomavirus vaccination. The Lancet 370:9592, 1031-1032
CrossRef393
H.-C. Kolberg. (2007) HPV-Impfung. Der Gynäkologe 40:9, 737-738
CrossRef394
K Ault, R Insinga, R Haupt, L Lupinacci, E Barr. (2007) Effects of quadrivalent human papillomavirus vaccination – Authors' reply. The Lancet 370:9592, 1032-1033
CrossRef395
Mark Schiffman, Philip E Castle, Jose Jeronimo, Ana C Rodriguez, Sholom Wacholder. (2007) Human papillomavirus and cervical cancer. The Lancet 370:9590, 890-907
CrossRef396
Jessica A. Kahn, Susan L. Rosenthal, Abbigail M. Tissot, David I. Bernstein, Caitlin Wetzel, Gregory D. Zimet. (2007) Factors Influencing Pediatricians' Intention to Recommend Human Papillomavirus Vaccines. Ambulatory Pediatrics 7:5, 367-373
CrossRef397
B. Gellin, J. F. Modlin, E. Barr, G. Tamms. (2007) Quadrivalent Human Papillomavirus Vaccine. Clinical Infectious Diseases 45:5, 609-617
CrossRef398
(2007) Widespread immunization of young women could reduce the burden of HPV-related disease. Nature Clinical Practice Oncology 4:8, 447-448
CrossRef399
Electra Nicolaidou, Andreas D Katsambas. (2007) The burden of human papillomavirus infections and the expected impact of the new vaccines. Expert Review of Vaccines 6:4, 475-477
CrossRef400
Alejandro García Carrancá, Silvia C Galván. (2007) Vaccines against human papillomavirus: perspectives for controlling cervical cancer. Expert Review of Vaccines 6:4, 497-510
CrossRef401
Kevin A. Ault. (2007) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. The Lancet 369:9576, 1861-1868
CrossRef402
Joseph Monsonego. (2007) Vaccination préventive anti-papillomavirus État des lieux et perspectives. Oncomagazine 1:1-2, 8-12
CrossRef403
Jessica A Kahn, Robert D Burk. (2007) Papillomavirus vaccines in perspective. The Lancet 369:9580, 2135-2137
CrossRef404
Maurie Markman. (2007) Human papillomavirus vaccines to prevent cervical cancer. The Lancet 369:9576, 1837-1839
CrossRef405
Apoorva Mandavilli. (2007) Don't rush your vaccines. news@nature
CrossRef406
Baden, Lindsey R., Curfman, Gregory D., Morrissey, Stephen, Drazen, Jeffrey M., . (2007) Human Papillomavirus Vaccine — Opportunity and Challenge. New England Journal of Medicine 356:19, 1990-1991
Full Text407
Charo, R. Alta, . (2007) Politics, Parents, and Prophylaxis — Mandating HPV Vaccination in the United States. New England Journal of Medicine 356:19, 1905-1908
Full Text408
Agosti, Jan M., Goldie, Sue J., . (2007) Introducing HPV Vaccine in Developing Countries — Key Challenges and Issues. New England Journal of Medicine 356:19, 1908-1910
Full Text409
Sawaya, George F., Smith-McCune, Karen, . (2007) HPV Vaccination — More Answers, More Questions. New England Journal of Medicine 356:19, 1991-1993
Full Text410
Garland, Suzanne M., Hernandez-Avila, Mauricio, Wheeler, Cosette M., Perez, Gonzalo, Harper, Diane M., Leodolter, Sepp, Tang, Grace W.K., Ferris, Daron G., Steben, Marc, Bryan, Janine, Taddeo, Frank J., Railkar, Radha, Esser, Mark T., Sings, Heather L., Nelson, Micki, Boslego, John, Sattler, Carlos, Barr, Eliav, Koutsky, Laura A., . (2007) Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases. New England Journal of Medicine 356:19, 1928-1943
Full Text411
Elmar A Joura, Sepp Leodolter, Mauricio Hernandez-Avila, Cosette M Wheeler, Gonzalo Perez, Laura A Koutsky, Suzanne M Garland, Diane M Harper, Grace WK Tang, Daron G Ferris, Marc Steben, Ronald W Jones, Janine Bryan, Frank J Taddeo, Oliver M Bautista, Mark T Esser, Heather L Sings, Micki Nelson, John W Boslego, Carlos Sattler, Eliav Barr, Jorma Paavonen. (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. The Lancet 369:9574, 1693-1702
CrossRef412
Shalini L Kulasingam. (2007) Implementation of an HPV-Vaccination Program. Disease Management & Health Outcomes 15:3, 141-149
CrossRef413
Woong Shick Ahn. (2007) Recent Concepts of Human Papillomavirus Vaccine. Journal of the Korean Medical Association 50:9, 778
CrossRef
- Letters
